



ACCEPTED MANUSCRIPT • OPEN ACCESS

## Bioink with cartilage-derived extracellular matrix microfibers enables spatial control of vascular capillary formation in bioprinted constructs

To cite this article before publication: Margo Luchiena Terpstra *et al* 2022 *Biofabrication* in press <https://doi.org/10.1088/1758-5090/ac6282>

### Manuscript version: Accepted Manuscript

Accepted Manuscript is “the version of the article accepted for publication including all changes made as a result of the peer review process, and which may also include the addition to the article by IOP Publishing of a header, an article ID, a cover sheet and/or an ‘Accepted Manuscript’ watermark, but excluding any other editing, typesetting or other changes made by IOP Publishing and/or its licensors”

This Accepted Manuscript is © 2022 The Author(s). Published by IOP Publishing Ltd..

As the Version of Record of this article is going to be / has been published on a gold open access basis under a CC BY 3.0 licence, this Accepted Manuscript is available for reuse under a CC BY 3.0 licence immediately.

Everyone is permitted to use all or part of the original content in this article, provided that they adhere to all the terms of the licence <https://creativecommons.org/licenses/by/3.0>

Although reasonable endeavours have been taken to obtain all necessary permissions from third parties to include their copyrighted content within this article, their full citation and copyright line may not be present in this Accepted Manuscript version. Before using any content from this article, please refer to the Version of Record on IOPscience once published for full citation and copyright details, as permissions may be required. All third party content is fully copyright protected and is not published on a gold open access basis under a CC BY licence, unless that is specifically stated in the figure caption in the Version of Record.

View the [article online](#) for updates and enhancements.

# Bioink with cartilage-derived extracellular matrix microfibers enables spatial control of vascular capillary formation in bioprinted constructs

**Margo L. Terpstra<sup>1</sup>, Jinyu Li<sup>2</sup>, Anneloes Mensinga<sup>3</sup>, Mylène de Ruijter<sup>1</sup>, Mattie H.P. van Rijen<sup>1</sup>, Charalampos Androulidakis<sup>4,5</sup>, Costas Galiotis<sup>4,5</sup>, Ioannis Papantoniou<sup>5,6,7</sup>, Michiya Matsusaki<sup>2</sup>, Jos Malda<sup>1,3</sup>, Riccardo Levato<sup>3,1</sup>**

<sup>1</sup> Department of Orthopaedics, University Medical Center Utrecht, Utrecht, The Netherlands.

<sup>2</sup> Division of Applied Chemistry, Graduate School of Engineering, Osaka University, Suita, Osaka, Japan

<sup>3</sup> Department of Clinical Sciences, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands.

<sup>4</sup>Composites & Nanostructured Materials Lab, Department of Chemical Engineering, University of Patras, Patras, Greece

<sup>5</sup>Institute of Chemical Engineering Sciences, Foundation for Research and Technology - Greece (FORTH), Patras, Greece

<sup>6</sup>Skeletal Biology & Engineering Research Centre, Department of Development and Regeneration, KU Leuven, Leuven, Belgium.

<sup>7</sup>Prometheus the translational division of Skeletal Tissue Engineering, KU Leuven, Leuven, Belgium.

E-mail: R.Levato@uu.nl

## Abstract

Microvasculature is essential for the exchange of gas and nutrient for most tissues in our body. Some tissue structures such as the meniscus presents spatially confined blood vessels adjacent to non-vascularized regions. In biofabrication, mimicking the spatial distribution of such vascular components is paramount, as capillary ingrowth into non-vascularized tissues can lead to tissue matrix alterations and subsequent pathology. Multi-material three-dimensional (3D) bioprinting strategies have the potential to resolve anisotropic tissue features, although building complex constructs comprising stable vascularized and non-

1  
2  
3 vascularized regions remains a major challenge to date. In this study, we developed  
4 endothelial cell-laden pro- and anti-angiogenic bioinks, supplemented with bioactive matrix-  
5 derived microfibers (MFs) that were created from type I collagen sponges (col-1) and cartilage  
6 decellularized extracellular matrix (CdECM), respectively. HUVEC-driven capillary networks  
7 started to form two days after bioprinting. Supplementing cartilage-derived MFs to endothelial-  
8 cell laden bioinks reduced the total length of neo-microvessels by 29%, and the number of  
9 microvessel junctions by 37% after 14 days, compared to bioinks with pro-angiogenic col-1  
10 MFs. As a proof of concept, the bioinks were bioprinted into an anatomical meniscus shape  
11 with a biomimetic vascularized outer and non-vascularized inner region, using a gellan gum  
12 microgel suspension bath. These 3D meniscus-like constructs were cultured up to 14 days,  
13 with in the outer zone the HUVEC-, mural cell-, and col-1 MF-laden pro-angiogenic bioink, and  
14 in the inner zone a meniscus progenitor cell- and CdECM MF-laden anti-angiogenic bioink,  
15 revealing successful spatial confinement of the nascent vascular network only in the outer  
16 zone. Further, to co-facilitate both microvessel formation and meniscus progenitor cell-derived  
17 matrix formation, we formulated cell culture medium conditions with a temporal switch.  
18 Overall, this study provides a new strategy that could be applied to develop zonal biomimetic  
19 meniscal constructs. Moreover, the use of ECM-derived MFs to promote or inhibit capillary  
20 networks opens new possibilities for the biofabrication of tissues with anisotropic  
21 microvascular distribution. These have potential for many applications including *in vitro*  
22 models of vascular-to-avascular tissue interfaces, cancer progression, and for testing anti-  
23 angiogenic therapies.  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40

## 41 Introduction

42  
43 Biofabrication has great potential to produce living three-dimensional (3D) constructs  
44 that mimic native tissues, and that can be applied for tissue replacement, repair, or disease  
45 modeling<sup>1</sup>. Complex structures can be recreated by the precise deposition of selected  
46 biomaterials, cells, and bioactive molecules. However, the generation of vascular components  
47 remains a major challenge towards the generation of full-thickness tissue equivalents<sup>2</sup>.  
48 Networks of open channels that mimic vasculature have been produced and enable perfusion,  
49 for instance via bioprinting of sacrificial materials<sup>3,4</sup>. Yet, a major challenge remains in steering  
50 the formation of pervasive capillaries in a region-specific fashion, since functional  
51 microvessels are needed to provide nutrients throughout most, but not all, large living tissue  
52 constructs.  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 The recreation of capillaries *in vitro* has been widely studied. Endothelial cells can self-  
4 assemble into a capillary-like network, when cultured in a 3D environment with specific growth  
5 factors and mural cells<sup>5-7</sup>. Previous studies have shown how such microvessels can be guided  
6 and matured, by culturing the abovementioned cells in presence of type I collagen (col-1)  
7 microfibers (MFs). With these MFs, capillaries showed more open lumen and larger capillary  
8 diameters, contributing to the ability to recreate a more biomimetic *in vitro* engineered capillary  
9 network<sup>6</sup>. Such collagen MFs are promising candidates as bioink components to carry  
10 instructive signals for endothelial cells, as these can be easily resuspended in hydrogels or  
11 aqueous formulations without the need for chemical modifications.  
12  
13

14  
15  
16  
17  
18 Where the majority of native tissues is dependent on a vascular capillary network, in  
19 partly vascularized tissues the spatial distribution of microvessels is tightly defined. The  
20 coexistence of precisely confined vascular and avascular regions is a defining element of  
21 many tissues and organs, including the eye, the intervertebral disc (IVD), the osteochondral  
22 boundary, and the menisci<sup>8-10</sup>. Replacement strategies of such tissue structures upon damage  
23 with (bioprinted) biomimetic living constructs, requires the recapitulation of their microvascular  
24 distribution. Specifically, the knee joint meniscus, a specialized tissue that provides knee joint  
25 stability and transfers mechanical forces from the femur to the tibia, consists of a non-  
26 vascularized inner, transitional, and vascularized outer zone<sup>11</sup>. Menisci are the most frequently  
27 damaged tissue structure of the knee, and while their outer zone has the capacity to repair  
28 (small) injuries, this ability is lacking in the inner zone, a difference which is in part explained  
29 by the local presence or absence of vasculature<sup>12</sup>. Thus, meniscus injuries in the inner  
30 zone, or of a critical size, that are unable to heal by intrinsic repair mechanisms or otherwise  
31 surgical interventions, can be eligible for replacement therapies. Importantly, when  
32 microvasculature is not properly confined in its intended region, microvessel ingrowth  
33 accompanied with nerve infiltration can take place into non-vascular regions<sup>13-15</sup>. This can  
34 lead to changed local tissue characteristics, such as cellular composition and altered  
35 (extracellular) matrix deposition by resident cells, as typically observed in osteoarthritic (OA)  
36 menisci, in the degenerating IVD, and OA cartilage<sup>10,14-17</sup>. Therefore, it is essential to prevent  
37 infiltration of microvasculature into non-vascularized zones when generating an engineered  
38 tissue equivalent in which adjacent vascularized and non-vascularized zones natively co-exist.  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51

52 Strategies to spatially control microvasculature patterning are currently limited<sup>18</sup>. As  
53 such, it is paramount to develop precise (bio)fabrication strategies that guide the spatial  
54 formation of microvasculature, and where necessary, prevent the formation or infiltration of  
55 capillaries in avascular biofabricated structures during growth and maturation. Previously  
56 identified anti-angiogenic molecules often reside in tissues like articular cartilage or the IVD,  
57  
58  
59  
60

1  
2  
3 indicating a role in the preservation of their avascular nature<sup>19–21</sup>. Endostatin, a type XVIII  
4 collagen fragment present in (fibro)cartilage, inhibits vascular network formation *in vitro* and  
5 *in vivo*<sup>22,23</sup>. Also, chondroitin sulphate (CS), an important glycosaminoglycan (GAG) in  
6 cartilage tissue, inhibits endothelial-cell network formation *in vitro*<sup>24</sup>. Next, chondrocyte-  
7 derived extracellular matrix (ECM) reduces endothelial cell-derived network formation *in vitro*,  
8 and prevents microvessel ingrowth *in vivo*<sup>25</sup>. Such tissue fractions or molecules can thus be  
9 promising supplements for printable bioinks to prevent the formation of endothelial-cell  
10 mediated network formation.  
11  
12

13  
14  
15  
16 In this study, we present a versatile strategy to steer endothelial cells to spatially  
17 reorganize into capillaries within a hydrogel, by the supplementation of MFs with pro- and  
18 anti-angiogenic potential. To generate constructs with a zonal vascular distribution and  
19 complex anatomical geometries, we used extrusion-based bioprinting to bioprint multiple  
20 bioinks in a microgel suspension bath. To demonstrate the application of such bioinks, 3D  
21 bioprinted meniscus-shaped constructs were produced with a distinct outer vascular and inner  
22 avascular fibrocartiligenous region. The outer meniscal zone was comprised of a fibrin-based  
23 pro-angiogenic bioink with human umbilical vein endothelial cells (HUVECs), mesenchymal  
24 stem cells (MSCs), and col-1 MFs to support capillary formation. The inner meniscal zone was  
25 comprised of a fibrin-based anti-angiogenic bioink with meniscus progenitor cells (MPCs), and  
26 cartilage decellularized ECM (CdECM) MFs to inhibit formation of capillaries.  
27  
28  
29  
30  
31  
32  
33

34 The printable bioinks with pro- and anti-angiogenic potential presented in this study  
35 allow for the spatial distribution of distinct vascularized and non-vascularized tissue  
36 components, in complex-shaped architectures using our presented 3D bioprinting setup. This  
37 platform can be used for various applications, including the recreation of tissues with zonal  
38 vascularity, and testing models for mechanisms of angiogenesis, or new therapeutic  
39 strategies, including drug testing and screening.  
40  
41  
42  
43  
44  
45

## 46 Materials and methods

### 47 1. HUVEC and MSC co-cultures with MFs

#### 48 1.1. Collagen MF preparation

49 Type I (col-1) and type II collagen (col-2) MFs were prepared as described previously<sup>26</sup>.  
50 In short, porcine type I collagen sponges (Nippon ham, Osaka, Japan) were dehydrated and  
51 crosslinked at 200°C for 24 hours. Next, samples were homogenized in deionized water for 6  
52 minutes at 30.000 rpm (VH-10 homogenizer, Violamo, S10N-10G: 10 mm diameter and 115  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 mm probe length). Then, samples were subjected to ultrasonication (Ultrasonic processor  
4 VC50, 50 W, 20 kHz) for 100 rounds of 20 seconds, with 10 seconds of rest in between, while  
5 the tube was maintained in ice water. Lastly, the fibers were filtered through a 42  $\mu\text{m}$  pore size  
6 nylon mesh (PA-42u, AS ONE, Osaka, Japan) and lyophilized. Chicken-derived type II  
7 collagen (Nippon ham, Osaka, Japan) was crosslinked at 200°C for 6 hours, and similarly to  
8 type I collagen samples homogenized, sonicated, filtered and lyophilized.

9  
10  
11  
12  
13 Cartilage dECM MFs were derived from decellularized equine stifle articular cartilage  
14 powder, prepared as previously described<sup>27</sup>. In short, articular cartilage was removed from  
15 healthy equine stifle joints, with permission from the owners and in line with the ethical  
16 regulations of the institution. Cartilage slices were cut into chips of 1 cm<sup>2</sup>, lyophilized, ground  
17 in liquid nitrogen, and sieved through 0.71 mm pores. Decellularization was initiated with 6  
18 cycles of 4 hours 0.25% trypsin (25200072, Thermo Fischer Scientific), followed by a 4-hour  
19 incubation with 50 U mL<sup>-1</sup> DNase (DN-25, Sigma-Aldrich) and 1 U mL<sup>-1</sup> RNase (R6513, Sigma-  
20 Aldrich) in 10 mM Tris/HCl pH 7.5, and finalized with a 24-hour exposure of 1% Triton X-100  
21 (X100, Sigma-Aldrich). The decellularized powder was washed in deionized water for 6 cycles  
22 of 8 hours, and freeze-dried. After, the powder was further processed into MFs, by  
23 homogenization, sonication, filtering and freeze-drying, similarly as the col-1 and col-2 MFs.  
24 Before the use in cell-culture, all fibers were ultraviolet light (UV-light)-sterilized for at least 20  
25 minutes, and then resuspended in medium without fetal bovine serum (FBS).

## 36 1.2. Raman spectroscopy and atomic force microscopy (AFM)

37  
38 For AFM measurements, col-1, col-2, and CdECM MFs were resuspended in a vial  
39 with distilled water, and deposited on a SiO<sub>2</sub> substrate by spin coating. The SiO<sub>2</sub> substrate  
40 was treated by oxygen plasma before the spin coating. For Raman spectroscopy lyophilized  
41 MFs were used.

42  
43 Atomic force microscopy (AFM) measurements were performed using a Bruker Icon  
44 system. A ScanAsyst AFM tip with nominal stiffness of  $\sim 0.7 \text{ N m}^{-1}$  and tip radius of  $\sim 2 \text{ nm}$  was  
45 used for the measurements. The topography and stiffness obtained with the Quantitative  
46 Nanomechanical Mapping (QNM) mode available in the Bruker's software which directly  
47 converts the indentation data (i.e., force-displacements curves) to values of modulus. The  
48 theoretical approach for the conversion of the f-d curves to modulus has been described in  
49 detail elsewhere<sup>28</sup>. The maximum applied indentation force was kept in the range of  $\sim 1\text{--}4 \text{ nN}$ ,  
50 depending on the sample. For this force regime the mechanical response is linear elastic, thus  
51 the applied forces did not cause plastic deformation on the sample and did not affect the  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 topography of the samples. The scan rate varied in the range of 0.3-0.6 Hz. A relatively slow  
4 scan rate was required to obtain the modulus maps with sufficient clarity.  
5

6 Raman spectra were collected using a 785 nm laserline with a 100x objective. The  
7 exposure time and laser power were adjusted to collect noise free spectra depending on the  
8 sample. Constituents were revealed by assignment to specific frequencies found in literature  
9 for the Raman bands, including amide I and III, GAGs, amino acids and proteins.  
10  
11  
12

### 13 14 15 1.3. Isolation and culture of GFP-HUVECs, hMSCs, hMCs, and hMPCs

16 Green fluorescent (GFP)-HUVECs (cAP-001GFP, Angioproteomie) were expanded in  
17 type I collagen pre-coated culture flasks at a density of  $3 \times 10^3$  cells  $\text{cm}^{-2}$  up to 80% confluency  
18 in Endothelial Cell Growth Medium-2 (EGM-2) BulletKit Medium (CC-3162, Lonza). Culture  
19 flasks were pre-coated with  $50 \mu\text{g mL}^{-1}$  collagen I rat tail (354236, Corning) in 0.01 M HCl for  
20 one hour at  $37^\circ\text{C}$ , followed by two washes of phosphate-buffered saline (PBS). GFP-HUVECS  
21 in experiments were used in passage 7, and cultured in EGM-2 medium for expansion and  
22 differentiation.  
23  
24  
25  
26  
27

28 Human iliac crest bone marrow-derived MSCs were harvested from a patient (age 66,  
29 male) receiving total hip arthroplasty or spondylodesis surgery as described before. Informed  
30 consent was given, and a protocol was used approved by the local medical ethical committee.  
31 First, the mononuclear bone marrow fraction was separated by centrifugation with a Ficoll-  
32 Paque density gradient (GE Healthcare, The Netherlands). Then, they were cultured up to  
33 passage 4 in T175 culture flasks at a density of  $3 \times 10^3$  cells  $\text{cm}^{-2}$  up to 80% confluency, in  
34 MEM alpha (22561, Life Technologies) supplemented with 10% heat-inactivated FBS  
35 (Biowest), 0.20 mM L-ascorbic acid 2-phosphate (A8960, Sigma-Aldrich), 1%  
36 penicillin/streptomycin ( $100 \text{ U mL}^{-1}$ ,  $100 \mu\text{g mL}^{-1}$ , 15140122, Gibco), and  $1 \text{ ng mL}^{-1}$   
37 recombinant human basic bFGF (233-FB, R&D Systems). The hbMSCs were assessed for  
38 their ability to form HUVEC-supporting pericytes by the expression of  $\alpha$ -smooth muscle actin,  
39 and a pericyte-like morphology<sup>5</sup>. In experiments hbMSCs were used at passage 5, and culture  
40 medium was refreshed twice per week.  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50

51 Human meniscus cells (MCs) and human MPCs were isolated from OA menisci (MCs:  
52 male, 62 years; MPCs: female, 54 years) as described before<sup>29</sup>. In short, meniscus tissue was  
53 digested with 0.2% pronase for 2 hours at  $37^\circ\text{C}$ , and then 0.075% collagenase overnight. MCs  
54 were expanded at  $3 \times 10^3$  cells  $\text{cm}^{-2}$  up to passage 2 in MEM alpha, 10% heat-inactivated  
55 FBS, and 1% penicillin/streptomycin. MPCs were further selected by their differential adhesion  
56 to fibronectin, by culturing them on fibronectin coated culture flasks for 20 minutes, after which  
57  
58  
59  
60



1  
2  
3 unadhered cells were washed away. Polyclonal expansion was performed at  $2 \times 10^3$  cells  $\text{cm}^{-2}$   
4 up to passage 4 in Dulbecco's Modified Eagle Medium (DMEM), high glucose, GlutaMAX  
5 (319566, Gibco), 10% fetal calf serum (FCS) (HZ), 1% penicillin/streptomycin, non-essential  
6 amino acids (11140050, Gibco), 0.20 mM L-ascorbic acid 2-phosphate, and 5 ng bFGF per  
7 mL medium. Chondrogenic differentiation was induced by culturing in DMEM, high glucose,  
8 GlutaMAX, 1% ITS Premix (354352, Fisher Scientific),  $0.039 \mu\text{g mL}^{-1}$  dexamethasone (D8893,  
9 Sigma-Aldrich), 0.20 mM L-ascorbic acid 2-phosphate, 1% penicillin-streptomycin (15140122,  
10 Gibco), and  $10 \text{ ng mL}^{-1}$  transforming growth factor (TGF)- $\beta$ 1 (100-21, Peprotech).  
11  
12  
13  
14  
15  
16  
17

#### 18 1.4. GFP-HUVECs and MSCs co-culture in fibrin gels

19  
20 GFP-HUVECs and hbMSCs were co-cultured in fibrin bioinks, consisting of  $6.6 \text{ mg mL}^{-1}$   
21 bovine fibrinogen (F8630, Sigma-Aldrich) and  $2 \text{ U mL}^{-1}$  bovine thrombin (T4648, Sigma-  
22 Aldrich). At this stage, gelatin was not added to the formulation yet, as its main role was  
23 enabling bioink printability. Importantly, gelatin is rapidly and spontaneously dissolved as soon  
24 as the hydrogels are placed at optimal cell culture conditions ( $37^\circ\text{C}$ ) and thus diffuses out of  
25 the constructs<sup>30</sup>, therefore it is not meant to contribute to the cell behavior during the 14 days  
26 of duration of our experiments.  
27  
28  
29  
30  
31

32 First, cells were collected in a pellet at a concentration of 2.5 million GFP-HUVECs  
33 and 5 million hbMSCs  $\text{mL}^{-1}$  fibrin gel. Optionally, 0.25, 0.5, or 1% w/v MFs were collected in  
34 the same pellet. Secondly, the cell (and MF) pellet was resuspended in fibrinogen dissolved  
35 in saline with 1% sterile filtered bovine serum albumin (Roche) and 10 mM N-2-  
36 hydroxyethylpiperazine-N-2-ethane sulfonic acid (HEPES) (15630080, Gibco). Lastly,  
37 thrombin dissolved in medium without FBS was added to the mixture, and  $20 \mu\text{L}$  droplets were  
38 pipetted quickly at the bottom of a culture plate. After 30 minutes of gelation and adhesion,  
39 EGM-2 medium was added. Each group was performed in triplicate or quadruple. The co-  
40 cultures were kept for 14 days, refreshing the medium twice per week.  
41  
42  
43  
44  
45  
46  
47

#### 48 1.5. Effect of medium formulations on the co-culture of meniscal 49 (progenitor) cells with HUVECs and MSCs

50  
51 In order to identify suitable co-culture conditions needed for the maturation of a  
52 heterocellular meniscus-like construct, comprising a vascularized outer and fibrocartilage-like  
53 inner zone, the effect of thirteen different cell culture medium compositions was tested on the  
54 performance of HUVEC-driven network formation, and meniscus (progenitor) cell  
55 differentiation. For this, a  $20 \mu\text{L}$  fibrin hydrogel ( $6.6 \text{ mg mL}^{-1}$  fibrinogen crosslinked with 2U  
56  
57  
58  
59  
60



1  
2  
3 mL<sup>-1</sup> thrombin), not supplemented with MFs, containing GFP-HUVECs and MSCs was  
4 cultured in the same well as a fibrin gel with either MCs, MPCs, or a combination of MCs and  
5 MPCs. The MCs and MPCs were cultured at 2 million cells mL<sup>-1</sup> fibrin gel, and the MC and  
6 MPC (1:1) at 1 million cells mL<sup>-1</sup> of each cell type. MCs were used at passage 3, and the MPCs  
7 at passage 5 in experiments. In this experiment, no col-1 or CdECM MFs were incorporated  
8 into the fibrin gels, to make sure that the experimental outcomes were initiated by the medium  
9 conditions.

10  
11  
12  
13  
14  
15 The fibrin gels were cultured in cell culture medium compositions: 100% EGM-2  
16 medium, 100% chondrogenic differentiation medium with TGF-β1, 75% EGM-2 medium with  
17 25% chondrogenic differentiation medium with TGF-β1, 50% EGM-2 medium with 50%  
18 chondrogenic differentiation medium with TGF-β1, 25% EGM-2 medium with 75%  
19 chondrogenic differentiation medium with TGF-β1, and 100% EGM-2 medium with growth  
20 factors from chondrogenic differentiation medium (1% ITS Premix, 1.95 μl (1 mg mL<sup>-1</sup>)  
21 dexamethasone per 50 mL medium, and 10 ng mL<sup>-1</sup> TGF-β1). A medium switch was applied  
22 in several formulations: control groups with 14 days EGM-2, 14 days chondrogenic  
23 differentiation medium (with or without TGF-β1), 7 days EGM-2 and 7 days 75% EGM-2 with  
24 25% chondrogenic differentiation medium (with or without TGF-β1), 7 days EGM-2 and 7 days  
25 90% EGM-2 with 10% chondrogenic differentiation medium (with or without TGF-β1), 7 days  
26 EGM-2 and 7 days EGM-2 with either 25% ITS-Premix, dexamethasone, or TGF-β1.

27  
28  
29  
30  
31  
32  
33  
34  
35 All samples were stained for proteoglycans using safranin-O/Fast Green, and  
36 immunohistochemistry was performed for type I, and type II collagen. The extent of GFP-  
37 HUVEC network formation was measured using Angiotool<sup>31</sup>. Each group was performed in  
38 quadruplicate.

## 43 2. 3D bioprinting of MF-laden bioinks into multi-material constructs

### 44 2.1. Bioink preparation

45  
46  
47 The bioink for extrusion-based bioprinting was composed of 6.7 mg mL<sup>-1</sup> fibrinogen,  
48 2% w/v filter sterilized gelatin (type A, bloom 300, G1890, Sigma) all dissolved in a saline  
49 solution supplemented with 1% bovine serum albumin (BSA) and 10 mM HEPES, and 2.5  
50 million GFP-HUVECs mL<sup>-1</sup> with 5 million hbMSCs mL<sup>-1</sup>. After transferring the bioink into the  
51 printing cartridge, the mixture was placed at 4°C for 10 minutes, and then in a water bath at  
52 22°C for 20 minutes (room temperature).  
53  
54  
55  
56  
57  
58  
59  
60

## 2.2. Gellan gum suspension bath

A microgel suspension bath was prepared from 1% w/v gellan gum solution. First, 2% gellan gum (G1910, Sigma) was dissolved in sterile deionized water at 90°C for approximately one hour, to ensure sterilization. Then sterile 2x PBS was added in a 1:1 ratio, and heated to allow homogeneous mixing. After cooling down to room temperature, the solidified gel was transferred into a sterilized mixer jar. To incorporate a final thrombin concentration of 1U mL<sup>-1</sup> into the gellan gum, an equal volume of 1x PBS with 2U mL<sup>-1</sup> thrombin was added to the jar. The mixture was milled for one minute, and transferred into 50 mL tubes with a maximum volume of 25 mL. After 30 minutes of incubation, the tubes were spun down at 2576 Relative Centrifugal Force (rcf) for 10 minutes, and the supernatant was removed. After vortexing, this step was repeated until a volume of 12.5 mL gellan gum microgel remained.

## 2.3. Bioprinting

3D bioprinting experiments were performed with the 3D discovery bioprinter (regenHu, Switzerland), using two pneumatic-driven extrusion printheads. The nozzles used for both bioinks were conical with a diameter of 0.25 mm. G-codes were generated using BioCAD and BioCAM software (regenHu, Switzerland). During optimization, immortalized MSCs (iMSCs) were encapsulated at  $7.5 \times 10^6$  in the bioinks, representing the sum of HUVECs and MSCs, and stained with brilliant blue. The filament fusion test represents distances from 0.300 to 1.050 mm with steps of 0.050 mm, from which also a filament diameter was extracted ( $n = 52$ ). The filament collapse test was performed as before<sup>32</sup>. Briefly, pillars were 3D printed with digital light processing (DLP) (ATUM 3D), with gap sizes of 16, 8, 4, 2, and 1 mm between pillars, over which the bioink was suspended. The 9 x 9 mm squared 3D bioprinted structures have five horizontal and five vertical layers, with a z-step distance of 0.25 mm, a printing speed of 10 mm s<sup>-1</sup>, and an inter-line distance of 1.5 mm. A layer stacking analysis was performed on 4 constructs after printing and removal of the gellan gum microgel suspension bath. A meniscus model was obtained from an equine meniscus-derived  $\mu$ -computed tomography (CT) scan, and converted into a dual zone digital 3D model using ImageJ. Meniscus constructs were bioprinted with the pro-angiogenic bioink in the outer zone, containing  $2.5 \times 10^6$  HUVECs mL<sup>-1</sup> and  $5.0 \times 10^6$  MSCs mL<sup>-1</sup> with 0.5% w/v col-1 MFs, and an anti-angiogenic bioink in the inner zone, containing  $2.0 \times 10^6$  MPCs mL<sup>-1</sup> with 0.5% w/v CdECM MFs. Bioink filaments were programmed to have a distance of 0.600 mm between fiber centers, and a z-step distance of 0.25 mm. Large, rectangular-shaped blocks with a pro-angiogenic bioink and anti-angiogenic bioink compartment were designed using BioCAD, to assess matrix deposition after 14 days

of culture (L: 3.6 mm for the pro-angiogenic compartment + 7.2 mm for the anti-angiogenic compartment; D: 7.2 mm; H: 6 mm (24 layers)).

### 3. (Immuno)histochemistry and metabolic activity

#### 3.1. Histology

After 14 days, fibrin gels were fixated in 4% buffered formalin, and further processed by dehydration through graded ethanol series and xylene washes, and paraffin embedding. Samples were cut in slices of 5  $\mu\text{m}$ , and rehydrated before staining. Proteoglycans were stained with 0.125% safranin-O (Merck), and counterstained with 0.4% fast green (Sigma-Aldrich) and Weigert's hematoxylin (Clin-Tech). Presence of collagens was evaluated by immunohistochemistry using antibodies for type I collagen (EPR7785, Abcam; 1:400 in PBS/BSA 5%) and type II collagen (II-II6B3; DHSB; 1:100 in PBS/BSA 5%). First, sections were blocked with 0.3%  $\text{H}_2\text{O}_2$ , followed by antigen retrieval with 1 mg  $\text{mL}^{-1}$  pronase (Sigma-Aldrich) for 30 minutes at 37°C and 10 mg  $\text{mL}^{-1}$  hyaluronidase (Sigma-Aldrich) for 30 minutes at 37°C. Then, sections were blocked using 5% BSA in PBS w/v for 30 minutes, and incubated overnight with the primary antibody at 4°C. The next day, type II collagen sections were incubated with a 1:100 goat-anti-mouse IgG horseradish peroxidase (HRP)-conjugated in 5% BSA in PBS w/v (P0447, DAKO) for one hour, and type I collagen sections with Envision + System-HRP anti-rabbit (K4003, DAKO), for 30 minutes at room temperature. Both stainings were visualized using 3,3'-diaminobenzidine (DAB, Sigma-Aldrich), counterstained with Mayer's hematoxylin (Klinipath) and mounted in DPX mounting medium (Merck).

#### 3.2. CD31 / $\alpha$ -SMA immunohistochemistry

The presence of endothelial cell marker CD31 and pericytes was shown with a CD31 immunohistochemistry staining. Samples were fixated in 4% buffered formalin, permeabilized with 0.2% triton for 30 minutes, and blocked with 5% BSA for 30 minutes. Then, samples were incubated with the primary antibody CD31 (1:20, mouse anti-human, M0823, Dako) for 1.5 hours, washed with PBS-Tween, and incubated with a biotinylated secondary antibody (1:200, sheep anti-mouse, GE Healthcare, RPN1001v1) for 1 hour. After, samples were incubated with a tertiary antibody (streptavidin Alexa fluor 488, Thermofischer S32354) and  $\alpha$ -smooth muscle actin (SMA) (1:300, clone 1A4, Cy3, C6198, Sigma Aldrich) for 1 hour, and finally incubated with 4',6-diamidino-2-phenylindole dihydrochloride (DAPI) staining (100 ng  $\text{mL}^{-1}$ , Sigma). Antibodies were all diluted in 5% BSA in PBS w/v.

### 3.3. Imaging

Imaging of fluorescent samples was performed using the SP8 confocal microscope (Leica), Thunder microscope (Thunder, Leica), or fluorescent microscope (Olympus IX 53). Samples (immuno)histologically stained for type I and II collagen, and safranin-O/fast green, were imaged using the Olympus BX51 microscope (Olympus DP70 camera, Hamburg, Germany)

### 3.4. Metabolic activity assay

Metabolic activity was assessed with an alamar blue assay on live samples. First, 5.54 mg Resazurin sodium salt (B21187, Alfa Aesar) dissolved in 50 mL PBS was sterile filtered. Samples were washed with PBS twice, and then incubated with culture medium supplemented with 10% Resazurin sodium salt solution for 4 hours at 37°C. Fluorescence was measured with an excitation of 544 nm and emission of 620 nm using a fluorescence microplate reader (Fluoroskan Ascent FL, Thermo LabSystems). After, samples were washed with PBS and proceeded in culture.

## 4. Statistical analyses

The vessel length and number of junctions were measured using AngioTool v. 0.6a (02.18.14)<sup>31</sup>. All statistical analyses were performed with GraphPad Prism 8.3.0 (538). Results were presented as mean  $\pm$  standard deviation, or median (inter quartile range (IQR)). The MF length and diameter measurements needed transformation following  $y_{\text{new}} = \log(y)$ . Statistical differences were tested using a Kruskal wallis test and Dunn's multiple comparison post-hoc test, separately comparing between concentrations within one MF type, different MF types with the same concentration, and lastly comparing all groups to the group without MFs. The effect of MFs on total vessel length and number of junctions was tested using a mixed model, and Sidak's multiple comparison test with a single pooled variance. A mixed-model with Geisser-Greenhouse correction, and post-hoc Tukey's multiple comparison test was performed for measurements on the metabolic activity of HUVECs and MSCs when cultured with 0.25, 0.5 and 1% MFs, and as well for the measurement on metabolic activity of HUVECs and MSCs that were bioprinted into squared 3D constructs, in four different concentrations. The effect of cell concentrations on construct shrinkage was tested using a mixed model with Geisser-Greenhouse correction, and Dunnett's multiple comparison test. Generally, statistical significance was considered when  $p \leq 0.05$ .

## Results

### Characterization of the MFs

Although all the source materials were processed under the similar conditions, MFs from different ECM components displayed different geometrical features (Figure 1). Namely, the median (IQR) length of CdECM MFs was significantly higher (109.5 (63.0-167.5)  $\mu\text{m}$ ) compared to the median lengths of col-1 (11.5 (7.0-24.3)  $\mu\text{m}$ ) and col-2 MFs (28.0 (10.0-50.0)  $\mu\text{m}$ ) (Figure 1(a)). Where the median diameter of CdECM MFs (4.0 (3.0-6.0)  $\mu\text{m}$ ) was similar to col-1 MF (4.0 (3.0-6.0)  $\mu\text{m}$ ), it was lower than the diameter of col-2 MFs (5.0 (4.0-8.0)  $\mu\text{m}$ ) (Figure 1(b)).

The AFM topography measurements revealed that both the col-1 and col-2 MFs were composed of assemblies of smaller nanoscale fibers (Figure 1(g)). The smaller fibers within the col-1 MFs were aligned, while within in the col-2 MFs they formed a randomly oriented mesh-like structure. The CdECM MFs did not consist of individual nanofibers, but presented round, edge-shaped structures. The local elastic modulus of the MF, mapped by nanoindentation with the AFM device, was found to be in the range of  $\sim 0.58 - 1.1$  GPa for the col-1 MFs,  $\sim 0.13 - 0.17$  GPa for the col-2 MFs, and between  $\sim 0.22 - 0.52$  GPa for CdECM MFs. These values agree very well with experimental and theoretical findings presented in other studies concerning collagen fibrils<sup>33</sup>.


Raman spectroscopy demonstrated that all experimental groups share their most prominent peak in the frequency  $\sim 1250$   $\text{cm}^{-1}$ , which corresponds to amide III (Figure 1(h)), Supplementary Table 1). Comparing the peak ratios with other bands for the same material, it follows that amide-III is more abundant in col-2 and CdECM MFs compared to col-1 MFs. Common spectral bands are identified also in the frequency  $\sim 1000$   $\text{cm}^{-1}$  and  $\sim 1670$   $\text{cm}^{-1}$ , corresponding to  $\nu_s$  (C-C) Phenylalanine and amide I, respectively and the  $\text{CH}_2$  and  $\text{CH}_3$  bending bands at  $\sim 1450$   $\text{cm}^{-1}$ . The latter are ascribed primarily to collagen chemical species, however respective bands of lipids may also contribute in the same spectral range. Two additional weaker bands at  $\sim 1044$  have been used in order to predict the amount of GAGs in cartilage samples<sup>34</sup> and in this study this peak was only observed for the col-2 MFs while it was not detected in the col-1 and CdECM MF samples (Supplementary Table 1). The latter was expected, as it was previously shown that the trypsin treatments, part of the decellularization process, deprives cartilage tissue from GAGs<sup>27</sup>. In order to compare across samples, ratio intensities of common spectra across samples were used (Table 1). When comparing the ratios of other peak intensities with interest to the application, we determined that intensity ratios of  $I_{920}/I_{1675}$  reflected a difference in proline residues in respect to the Amide

I peaks. Where col-2 and CdECM MF ratios were similar, the ratio of col-1 MFs showed a large difference in respect to the other two conditions. In addition, the same correlation was seen for  $I_{873}/I_{1675}$  and  $I_{1001}/I_{1675}$  reflecting the ratios of peak intensities that are characteristic of hydroxyproline and Amide I, and phenylalanine and Amide I respectively<sup>35</sup>. These findings suggest that col-2 and CdECM MFs possess a lower presence of the aminoacids proline, hydroxyproline and phenylalanine in their collagen fibers in respect to col-1 MFs.

Table 1. Intensity ratios of selected Raman peaks characteristic of proline, hydroxyproline and amide I.

	Proline (I853) /Amide I (I1675)	Hydroxyproline (I873) / Amide I (I1675)	Phenylalanine(I1001) / amide I (I1675)
Col-1 MFs	0.94 ± 0.12	0.65 ± 0.13	0.98 ± 0.15
Col-2 MFs	0.34 ± 0.22	0.23 ± 0.13	0.31 ± 0.18
CdECM MFs	0.18 ± 0.08	0.22 ± 0.09	0.26 ± 0.11





**Figure 1:** Characterization of col-1, col-2 and CdECM MFs. (a, b) The length and diameter distribution of col-1 ( $n = 142$  and  $n = 136$ ), col-2 ( $n = 435$  and  $n = 336$ ), and CdECM MFs ( $n = 204$  and  $n = 293$ ) is presented. (c-f) Macroscopic and microscopic photographs capture the col-1, col-2 and CdECM MF morphology. (g) AFM displays surface roughness (top) and elastic modulus (bottom) of the MFs on a squared surface of approximately  $9 \mu\text{m}^2$ . (h) Raman spectroscopy revealed content differences between MFs, indicated by the presence of peaks at 853 (typically associated with proline), 873 (hydroxyproline), 920 (proline), 1001 (phenylalanine), 1044 (GAGs), 1250 (amide III), 1450 ( $\text{CH}_2$  and  $\text{CH}_3$  bending for collagen species, or lipids), and 1670 (amide I)  $\text{cm}^{-1}$ .


## CdECM MFs reduce HUVEC-driven network formation

We assessed the effect of col-1, col-2 and CdECM MFs on HUVEC-driven network formation at 0.25, 0.5, and 1% w/v, by encapsulating HUVECs and MSCs with MFs in a 3D fibrin gel ( $6.6 \text{ mg mL}^{-1}$ ) (Figure 2(a),  $n = 9$  for all groups). The endothelial cells that formed capillary-like structures were surrounded by pericyte-like,  $\alpha$ -smooth muscle actin positive MSCs (Figure 2(b)). By quantitative measurements of GFP-HUVEC networks, it was found that CdECM MFs significantly reduced the total vessel length and number of junctions in a dose-dependent manner, as compared to the same concentrations of col-1 and col-2 MFs (Figure 2(c-d)). In fact, the supplementation of 1% w/v CdECM MFs resulted in the strongest reduction of HUVEC-driven network formation compared to col-1 MFs, more specifically, reducing the total vessel length by 34% (after 7 days) and 29% (after 14 days). Additionally, the total number of junctions decreased with 41% (after 7 days) and 37% (after 14 days) (Figure 2(d)). Based on both the measured total vessel length and total number of junctions, beside 1%, also 0.25 (on day 7) and 0.5% (day 7 and 14) CdECM MFs significantly reduced HUVEC-driven network formation compared to concentration-matched col-1 and col-2 MFs.

In fact, except for 0.25% w/v CdECM on day 14, the total vessel length on day 7 and 14 was significantly lower in presence of CdECM (day 7: 0.25%:  $399.7 \text{ mm} \pm 55.1$ ; 0.5%:  $385.6 \pm 64.8$ ; 1%:  $288.9 \pm 62.0$ ) of the corresponding concentration (Figure 2(c)). Also, the total vessel length was reduced significantly in presence of 1% w/v CdECM compared to CdECM 0.25% and 0.5% w/v on day 7 and 14. Also, the group with encapsulated col-1 MFs showed a significantly increased total vessel length on day 14, compared to the 0.25 and 1% w/v col-1 groups, as well as the no-MF group. Similar significant differences were found for the total number of junctions, with a significant reduction when cultured with of 0.5% and 1% w/v of CdECM MFs. The MFs did not show any auto-fluorescence when exposed to the 470 nm light source used to visualize the GFP-positive cells, and did thus not interfere with the vessel length measurements (Supplementary Figure 1). In general, regardless of the material of origin of the fibers, the addition of MFs reduced metabolic activity of the embedded cells significantly on day 1 and 14, compared to no addition of MFs (Figure 2(e)). Only on day 1, a concentration-dependent reduction in metabolic activity was found related to col-2 and CdECM MF concentration. In fact, the HUVEC and MSC co-cultures supplemented with 1% w/v col-2 MF was decreased with 12% compared to both col-2 0.25% and 0.5% w/v. For CdECM MFs, the group with 1% MFs w/v presented a 9 and 11% drop compared to 0.25, and 0.5% CdECM MFs respectively. On day 7, no significant differences in metabolic activity were found that were related to the type of MF or increase in MF concentration. On day 14, only within the col-2 MF group a concentration dependent significant reduction was observed

1  
2  
3 (0.25% and 1% w/v), but not for the other MFs. The 0.25% CdECM MF group showed a  
4 significantly lower metabolic activity than the 0.25% w/v col-2 MF group. Lastly, in line with the  
5 results on total vessel length and number of junctions, on day 14, the 0.5% w/v col-1 group  
6 showed a significantly higher metabolic activity than the other col-2 MF groups, as well as the  
7 0.5% w/v col-2 and CdECM MFs.  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Accepted Manuscript



**Figure 2:** Effect of CdECM MFs on HUVEC-driven capillary network formation. (a) Fluorescent microscopy photographs of GFP-HUVECs, co-cultured with MSCs in a fibrin gel with 0.5% w/v col-1, col-2, or CdECM MFs after 14 days. From each sample photographs

1  
2  
3 were taken from the edge of the gel. (b) Confocal micrographs showed that GFP-HUVECs  
4 formed capillary-like structures in presence of col-2 MFs, surrounded by MSCs-derived  
5 pericytes. (c, d) The total vessel length and number of junctions were presented for the co-  
6 cultures in a fibrin gel, supplemented with col-1, col-2, and CdECM MFs at 0.25, 0.5 and 1%  
7 w/v, and a group without MFs. Each group is represented by a symbol. Statistical significance  
8 was only tested between groups with the same concentration of MFs, and between  
9 concentrations within one MF type. Significant differences between groups were indicated by  
10 the presence of the group specific symbols above the graph bar of the other group. In general,  
11 symbols for col-1 MFs were presented in dark grey, for col-2 MFs in light grey, and for CdECM  
12 MFs in red. Circles indicate a group with 0.25% w/v MFs, squares 0.5% w/v MFs, and triangles  
13 1% w/v MFs. (e) The metabolic activity was measured on day 1, 7, and 14 of culture (n = 9),  
14 following the same indication for significant differences between groups as in Figure 2(c-d). In  
15 general, statistical significance was considered  $p \leq 0.05$ .

### 26 27 3D printing of the bioinks

28  
29 An optimized bioink consisting of 2% w/v gelatin, and  $6.6 \text{ mg mL}^{-1}$  fibrin was  
30 successfully extrusion based-bioprinted into a gellan gum microgel-based supporting  
31 environment, serving as a base for an angiogenic and anti-angiogenic bioink (Figure 3(a)). To  
32 increase the viscosity of the ink, the 2% w/v gelatin concentration was selected over 2.5, 3,  
33 3.5, 4, and 5% w/v, since it allowed to extrude the ink as a continuous filament in the support  
34 bath at room temperature (data not shown). A filament collapse test was performed to assess  
35 the deformation that the printed filaments undergo when spanning across distanced support  
36 structure and the tendency of the material to sag under its own weight, as an indicator of its  
37 ability to preserve shape fidelity in the z-direction<sup>32</sup>. This assay was performed using the  
38 fibrinogen-gelatin bioink-laden with iMSCs to mimic the final HUVEC and MSC cell  
39 concentration (Figure 3(b)). We observed that, without the gellan gum support bath, filaments  
40 could not span the smallest distance of 1 mm at  $10 \text{ mm second}^{-1}$ , whereas within the support  
41 bath filaments could span over a distance of 16 mm without any gravity-induced deformation.  
42 Then, using the same iMSC-laden bioink, a filament fusion test showed that the average  
43 diameter of a printed filament (ft) was  $0.44 + 0.07 \text{ mm}$ . This specific test estimates the  
44 tendency of the ink to undergo deformation in the xy plane due to surface tension and  
45 viscoelasticity driven flow of the material prior to stabilization by crosslinking<sup>32</sup>. This  
46 information can be used to estimate the capacity of the ink to resolve sharp angles and to  
47 identify the smallest distance at which to adjacent filaments can be placed<sup>32</sup>.




1  
2  
3 It also revealed this minimum possible distance between two parallel printed filaments  
4 (measured from filament center to center) ( $f_d$ ), was 0.6 mm (Figure 3(c)). When also taking  
5 into account that the filament fusion length in the corner should not exceed 2x the filament  
6 diameter, the optimal inter-filament distance was approximately 1 mm (Figure 3(d)). In this  
7 way, an inter-filament distance can be defined, while maintaining shape fidelity within a 3D  
8 printed structures.  
9

10  
11  
12  
13 It was expected that the addition of MFs would not influence the bioink printability in a  
14 relevant way, since gelatin primarily defines the bioink's viscosity, as the sole fibrinogen  
15 solution, with and without microfibers, behaves as a non-viscous fluid, and is therefore not  
16 printable. Also, it was shown before that the addition of 0.5 and 1% w/v col-1 MFs to a fibrin-  
17 based bioink resulted in similar rheological properties as compared to the bioink without MFs<sup>6</sup>.  
18  
19

20  
21 As the support bath contributes to the printed filament resolution also by "templating"  
22 the filament with a surface roughness which profile is dependent on the size and shape of the  
23 microgel particles<sup>36</sup>, the geometrical features of the gellan gum microgel suspension bath  
24 particles were characterized. The particles displayed an average (maximum) diameter of  $20.7$   
25  $\pm 8.6$   $\mu\text{m}$ , and showed an irregular, polygonal morphology (Figure 3(e)). For 9 x 9 mm squared  
26 constructs of 10 layers high with a programmed z-stacking distance of 0.25 mm, which  
27 theoretically leads to a construct height of 2.5 mm, a layer stacking characterization showed  
28 that the construct height was  $2.42 \pm 0.22$  mm. Additionally, no delamination has taken place  
29 between layers. The optimal ratio of HUVECs and MSCs for network formation after  
30 bioprinting with the fibrin-gelatin bioink was found to be 1:2, more specifically embedding  $2.5$   
31  $\times 10^6$  HUVECs  $\text{mL}^{-1}$ , and  $5 \times 10^6$  MSCs  $\text{mL}^{-1}$ . This was compared to a 2:1 ratio with the same  
32 HUVEC concentration, and a 1:2 and 2:1 ratio using  $1.25 \times 10^6$  HUVECs  $\text{mL}^{-1}$ , by subjective  
33 qualitative fluorescent microscopy observations (Figure 3(f)). The metabolic activity of 3D  
34 printed constructs increased over time for all the experimental groups, confirming cell viability  
35 over a 14-day period in all groups (Figure 3(g)). The higher metabolic activity levels were  
36 detected in the groups homing the highest cell density, and the highest increase in metabolic  
37 activity over time in the group homing the lowest cell density. This indicates a higher rate of  
38 cell proliferation when seeded at a lower cell density, which is consistent with what was  
39 previously reported for MSCs<sup>37</sup>. This implies that in all groups individual cell metabolic activity  
40 increased and/or cell proliferation took place, and that, most likely, in the lowest cell density  
41 group mainly MSCs proliferation led to the increase in metabolic activity.  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55

56 Altogether, a fibrinogen-based bioink was optimized for bioprinting in a thrombin  
57 containing microgel support bath, enabling the formation of fibrin-based filaments with an  
58 average diameter of  $0.44 \pm 0.07$  mm.  
59  
60






1  
2  
3 **Figure 3:** Extrusion-based bioprinting of fibrinogen and gelatin cell-laden bioink. (a)  
4 Macroscopic photograph of the extrusion-based bioprinting setup with a microgel support  
5 bath. (b) A filament collapse test with an iMSCs-laden fibrin and gelatin bioink revealed that  
6 filaments collapsed without gellan gum support bath, but remained intact when printed in the  
7 support bath ( $n = 2$ ). (c) A filament fusion test showed that this bioink could only be bioprinted  
8 into a gellan gum support bath (top), as filaments did not retain shape fidelity without it (bottom)  
9 ( $n = 2$ ). (d) The ratio between the fused filament segment ( $f_s$ ) and the diameter of an individual  
10 filament ( $f_t$ ), was plotted as a function of the inter-filament distance ( $f_d$ ) (distance from center  
11 to center) ( $n = 33$   $f_s/f_t$  measurements). In a printed meandering pattern,  $f_s$  measures the length  
12 of the portion of the pattern in which two adjacent filaments fuse together when connected by  
13 a corner of the meander, and therefore in an ideal print,  $f_s/f_t = 1$  for all  $f_d > f_t$ . This plot reveals  
14 the minimum inter-filament distance at which adjacent filaments do not fuse at all, and, at the  
15 same time, indicates the extent of the deviation of the print from a sharp  $90^\circ$  turn, as a function  
16 of the designed inter-filament spacing. (e) The distribution of gellan gum microgel maximum  
17 diameters. (f) GFP-HUVECs network formation was visualized after 14 days of bioprinting four  
18 different HUVEC and MSC concentrations in the fibrinogen-gelatin formulation ( $n = 8$  samples  
19 for all groups except for the  $2.5/5$  million cells  $\text{mL}^{-1}$ , where  $n = 6$  samples). (g) Also, metabolic  
20 activity of the groups were measured on day 1, 7, and 14.  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Co-culture of HUVECs with MSCs and meniscus (progenitor) cells, and their 3D bioprinting into a zonal meniscus-shaped construct

We demonstrate that both the successful formation of HUVEC-driven networks, and type I collagen deposition by MPCs was achieved by culturing the cells in EGM-2 medium first, and then in a combination of EGM-2 and chondrogenic differentiation medium (Figure 4). In total, 13 medium conditions have been assessed to investigate the differentiation capacity of HUVECs with MSCs to form capillary networks, and of meniscus (progenitor) cells to deposit matrix proteins. For this screening, the HUVECs and MSCs were encapsulated in a fibrin gel (6.6 mg mL<sup>-1</sup>), and cultured in the same well as a fibrin gel in which meniscus (progenitor) cells were encapsulated. More specifically, HUVECs with MSCs were encapsulated in a 20  $\mu$ L fibrin-based hydrogel (6.6 mg mL<sup>-1</sup> fibrinogen and 2U mL<sup>-1</sup> thrombin), and cultured in the same well as MPCs encapsulated in a similar fibrin-based hydrogel. MFs were not added to the fibrin gels yet, to make sure the observed matrix formation was initiated by the medium conditions alone. First, EGM-2 medium was applied for 7 days, followed by either a 75/25 or 90/10 v/v ratio of EGM-2/chondrogenic differentiation medium containing TGF- $\beta$ 1. In general, medium groups that contained TGF- $\beta$ 1, facilitated the expression of type I collagen by the MPCs, but not type II collagen (Figure 4(b)). Interestingly, the same medium formulations without TGF- $\beta$ 1 did not stimulate MPCs to deposit type I collagen. Also, in presence of a higher concentration chondrogenic differentiation medium, the MPCs expressed more type I collagen (75/25 compared to 90/10) (Figure 4(b)). Beside the use of multiple medium formulations during the 14-day culture time, we also assessed the use of single culture medium formulations during 14 days. The application of five ratios of EGM-2/chondrogenic differentiation medium (100/0, 75/25, 50/50, 25/75, and 0/100 v/v), revealed that MCs, MPCs, and MCs with MPCs produce type I collagen in presence of 25% or more chondrogenic differentiation medium that included TGF- $\beta$ 1 (Supplementary Figure 2(a)). The MCs with MPCs in EGM-2 medium (100/0) expressed very little type I collagen. Type II collagen and proteoglycan deposition were not or hardly detected in any of the medium conditions (Supplementary Figure 2(b-c)).

HUVEC-driven network formation was stable in almost all culture medium conditions that initiated with 7 days of EGM-2 medium (Figure 4(b-d)). Only the supplementation of 25% TGF- $\beta$ 1 to EGM-2 medium on day 8 to 14 (group H) resulted in a significant reduction of the quantified total vessel length (day 1-14 EGM-2 medium: 427  $\pm$  21 mm, group H: 234  $\pm$  55 mm) and total number of junctions (day 1-14 EGM-2 medium: 3186  $\pm$  157 mm, group H: 1319  $\pm$  521 mm) (Figure 4(c-d)). During day 8-14, the addition of 10 or 25% v/v chondrogenic

1  
2  
3 differentiation medium with or without TGF- $\beta$ 1, or the supplementation of 25% ITS-Premix or  
4 dexamethasone to EGM-2 medium did not significantly reduce the abundance of  
5 microvessels. When HUVECs and MSCs were cultured in five different ratios of EGM-  
6 2/chondrogenic differentiation medium (75/25, 50/50, 25/75, 100/0 v/v) for 14 days, the  
7 microvessel network either underwent a collapse before day 14 (75/25, 50/50, 25/75 v/v), or  
8 did not initiate network formation (0/100 v/v) (Supplementary Figure 3, fluorescent  
9 micrographs not shown). The presence of chondrogenic differentiation medium induced  
10 HUVEC and MSC-laden hydrogel edges to shrink and eventually curl up. This effect was  
11 concentration dependent, resulting in spherical shaped hydrogels when the samples were  
12 cultured in chondrogenic differentiation medium (0/100 v/v) (data not shown). Since  
13 microvessel network formation was not supported in this condition, we visualized deposition  
14 of type I, II collagen and proteoglycan deposition to determine whether MSC may have entered  
15 the chondrogenic lineage. Type I collagen was observed in all five medium conditions, yet, in  
16 presence of EGM-2 medium, it was mainly aligned along the capillary-like structures. In  
17 general, type II collagen was hardly detectable, and proteoglycans seemed absent in all  
18 groups (Supplementary Figure 3).  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




**Figure 4:** The effect of ten culture medium conditions on the co-culture of HUVECs with MSCs and MPCs. (a) One fibrin hydrogel with HUVECs and MSCs and a second hydrogel with MPCs

1  
2  
3 were cultured in one well in medium compositions A-J for 14 days. Medium was composed of  
4 EGM-2 medium in combination with chondrogenic differentiation medium (chon. dif.), with or  
5 without TGF- $\beta$ 1. (b) Fluorescent micrographs of GFP-HUVECs, as well as micrographs of  
6 MPC type I and II collagen immunohistochemistry were presented for each cell culture  
7 condition. (c, d) Total vessel length and number of junctions of HUVEC-driven network  
8 formation was measured on day 14, and significantly lower in group H compared to control  
9 group A. GFP-HUVECs were not detectable (N.D.) in groups I and J. For group A-H  $n = 5$ , for  
10 groups J and I  $n = 4$ .

11  
12  
13  
14  
15  
16  
17  
18 In order to prove that the pro- and anti-angiogenic bioink can be 3D bioprinted into a  
19 complex 3D structure, an anatomical meniscus construct was bioprinted, using a  $\mu$ CT-image  
20 of a native equine meniscus as a blueprint. Col-1 MFs have previously been shown to enhance  
21 the formation of endothelial cell-derived microcapillary-like structures<sup>6</sup>, and was therefore  
22 selected as a suitable microfiber for the vascularized zone, as compared to col-2 MFs. In our  
23 MFs screening study, col-2 MFs served as a control to exclude that this specific collagen  
24 component could be responsible for the inhibition of vascularization observed in the CdECM  
25 MFs. Regarding the choice of cells, MPCs were preferred over MCs, due to their superior  
26 proliferative ability and stability over extensive passaging when compared to MCs<sup>29</sup>. Moreover,  
27 this ability is particularly beneficial for bioprinting applications, for which high cell numbers are  
28 typically required. The bioprinted model consisted of a vascularized outer and non-  
29 vascularized inner zone (Figure 5(a-b)). The pro-angiogenic bioink, consisting of 6.6 mg mL<sup>-1</sup>  
30 fibrinogen and 2% w/v gelatin, used for the outer zone was supplemented with 0.5% w/v col-  
31 1 MFs, and contained HUVECs and MSCs, while the inner zone anti-angiogenic bioink, also  
32 consisting of 6.6 mg mL<sup>-1</sup> fibrinogen and 2% w/v gelatin, was supplemented with 0.5% w/v  
33 CdECM MFs, and further consisted of MPCs (Figure 5(a)). The bioinks were bioprinted into a  
34 gellan gum support bath supplemented with thrombin. With 2.5 mL of pro- and anti-angiogenic  
35 bioink, approximately 5 larger meniscus constructs can be bioprinted. The repeatability of  
36 bioprinting the constructs was good, with the difference constructs displaying comparable  
37 shape and size. Moreover, no noticeable difference in terms of cell behavior (i.e. formation of  
38 vascular networks by the encapsulated HUVECs) could be observed between the first and the  
39 last construct to be printed, despite of the extra time out of the optimal culture conditions  
40 experienced by the cells in the printing cartridge. The 3D bioprinted meniscus models were  
41 cultured for up to 14 days, and HUVEC-driven networks formed in the outer region, but not in  
42 the inner non-vascularized region (Figure 5(c), Supplementary Figure 4). In addition to dual  
43 zone meniscus constructs, large rectangle-shaped constructs were bioprinted with an inner  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3 and outer zone composed of the same bioinks as the meniscus construct. The sizes of the  
4 vascularized and non-vascularized block-shaped zones was designed in a way that the  
5 maximum distance of cells to the cell culture medium was similar to that of the large meniscus  
6 construct (18.6 mm in length). An advantage of this block-shaped construct over a more  
7 organic-shaped meniscus construct, is that during histological assessments, the vascularized  
8 and non-vascularized zone were more easily distinguishable from a macroscopic assessment.  
9  
10 The larger printed constructs were used to determine type I collagen matrix deposition after  
11 14 days of culture (Figure 5(d)). Constructs were cultured in medium formulation D, including  
12 EGM-2 medium from day 1-7 and 75% EGM-2 with 25% v/v chondrogenic differentiation  
13 medium from day 8-14. This formulation was successful in enabling MPCs to deposit type I  
14 collagen in a small fibrin gel (Figure 4(b)). We observed that in the middle of the construct, the  
15 vascularized zone presented open lumen from capillary-like structures, around which type I  
16 collagen was deposited (Figure 5(d)). In the non-vascularized zone, MPC-derived type I  
17 collagen deposition was found in very small amounts in the middle of the construct, but more  
18 abundantly on the edges of the construct. The type I collagen deposition was expected, due  
19 the large construct size, less abundant compared to the 20  $\mu$ l casted fibrin gels (Figure 4(b)).  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



**Figure 5:** Bioprinting a meniscus-shaped construct with a pro- and anti-angiogenic bioink. (a) A meniscus-shaped construct was bioprinted with a pro-angiogenic outer zone consisting of HUVECs, MSCs, and col-1 MFs, and an anti-angiogenic inner zone, consisting of MPCs with CdECM MFs. (b) A meniscus stl file was obtained from an equine meniscus  $\mu$ CT scan, and used as a model to bioprint a meniscus construct of 24 layers with the developed bioinks. (c) The interface of the outer vascularized, and inner non-vascularized zone is visualized with fluorescent (top), and brightfield (bottom), micrographs, obtained with confocal microscopy on day 14, where the vascularized zone is located in the lower part of the micrograph, and the non-vascularized in the upper part, directly above the GFP-HUVECs. The construct was cultured in EGM-2 medium (day 0-7) and 75% EGM-2 with 25% (v/v) chondrogenic differentiation medium (day 8-14). (d) Type I collagen immunohistochemistry was performed

1  
2  
3 for the vascularized and non-vascularized zone. The staining for the non-vascularized zone  
4 was performed on an 18 mm long meniscus construct cultured up to day 14, where type I  
5 collagen deposition was present on the outer sides of the construct. The vascularized zone  
6 type I collagen staining was performed on a large bioprinted block-like structure, that  
7 resembles the thickness of the 18 mm meniscus construct. Microvessels with open lumen  
8 were observed in both the edge and the middle of the construct, and stained positive for type  
9 I collagen. Construct dimensions were 6.0 mm high, 7.2 mm in depth, and 3.6 mm in length  
10 for the vascularized zone, and 7.2 mm for the non-vascularized zone.  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Discussion

The possibility to precisely position vascular features, and subsequent engineered vessel networks, holds great potential for bioprinting constructs that capture the anisotropic composition of native tissues. While larger vessel structures can be included through the printing of sacrificial materials, patterning microcapillaries remains elusive<sup>4</sup>. Addressing this unsolved challenge has direct implications for the biofabrication of structures with a boundary between vascularized and avascular regions, for example as found in the different zones within menisci, or at the osteochondral interface.

In this study, we investigated a versatile, bioink design-based strategy to enable spatial control over capillary microvasculature formation within 3D bioprinted constructs. Two classes of bioprintable bioinks were introduced that either facilitate (pro-angiogenic) or inhibit (anti-angiogenic) microvessel formation *in vitro*, by the incorporation of extrudable MFs derived from different ECM components. Using extrusion-based 3D bioprinting, the two bioinks were deposited in a complex 3D organization, and able to locally steer the behavior of encapsulated co-cultures of HUVECs and MSCs, guiding their ability to self-assemble into microvascular networks.

First, MFs from different origins and chemistry were investigated in combination with fibrin, a biomaterial extensively characterized for its ability to sustain endothelial cells in culture, and a major component for several bioink formulations<sup>35,36</sup>. The fibrin-based pro-angiogenic bioink, consisting of HUVECs and MSCs, was supplemented with col-1 MFs, derived from porcine type I collagen sponges. Previously, it was shown that the addition of these col-1 MFs resulted in the formation of capillaries with larger diameters and open lumen *in vitro*<sup>6</sup>. The col-1 MFs are suggested to act as a bioactive adhesion side for endothelial cells. Increased expression levels of integrin- $\beta$ 1 by endothelial cells in the presence of col-1 MFs suggest a role of the receptor in this connection<sup>6</sup>.

The anti-angiogenic fibrin-based bioink was obtained via the supplementation of CdECM MFs, derived from equine cartilage dECM. These MFs effectively reduced HUVEC-driven network formation in a dose-dependent manner, compared to col-1 MFs. Noteworthy, this inhibiting effect did not correlate with a cytotoxic effect of the MFs. In fact, for all the bioink formulations, the cultured cells showed comparable levels of metabolic activity, regardless of the concentration or nature of embedded MFs. This indicates that the inhibitory effect is likely due to the CdECM MFs biochemical composition and/or physical properties. In addition, bioinks supplemented with col-2 MFs, did not lead to an impaired HUVEC-derived growth of capillary networks, suggesting that type II collagen, the most prominent protein in cartilage tissue and in the CdECM, does not seem to have anti-angiogenic properties.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47

The reason for the different effects of col-1, col-2 and CdECM MFs on angiogenesis may be sought in the biochemical compositions of the MFs. Raman spectroscopy has previously been used to assess quality characteristics of tissue engineered as well as native tissues such as cartilage tissues known to contain type II collagen<sup>38–40</sup>. Data obtained from Raman spectroscopy analyses confirmed that col-2 and CdECM MFs were more similar to each other than to col-1 MFs, considering that the relative peak intensities that correspond to proline, hydroxyproline, and phenylalanine were similar, but also lower in col-2 and CdECM samples, as compared to col-1 MFs. The resemblance between the two MFs is coherent with the abundance of type II collagen in native cartilage, even though col-2 and CdECM MFs were harvested from avian and equine sources respectively. The CdECM MFs were deprived from most GAGs and proteoglycans as an effect of the decellularization process<sup>27</sup>, whereas residual GAGs could be identified in the Raman spectrum of the col-2 MFs. Yet these MFs did not successfully inhibit capillary formation in the fibrin bioinks, even though, some GAGs, including CS have been reported to exert anti-angiogenic activity<sup>41</sup>. Beside GAGs, other molecules with inhibiting potency may still be present in the CdECM MFs. Previously, microvascular inhibiting molecules have been identified in tissues with an avascular nature, such as the inner meniscal zone, cartilage tissue, and the nucleus pulposus<sup>22–24,41,42</sup>. These include (shark) cartilage fractions, chondrocyte-derived ECM, or the soluble secretome from cells residing in avascular tissues<sup>15,16,20,21,42</sup>. Specific molecules identified in cartilaginous tissue include endostatin or collagen XVIII fragments, and the type IIB collagen NH<sub>2</sub>-propeptide<sup>22,41,43</sup>. Beside its biochemical content, the generation of MFs by homogenization and sonication resulted in CdECM MFs with a significantly higher and less homogeneous length distribution compared to col-1 MFs. The CdECM MF median diameter was not significantly different from col-1 MFs, yet the presence of a few CdECM MFs with larger diameters may influence the physical bioink structure at micrometer level within the fibrin gels. These larger MFs can result in denser and a less homogeneous distribution in the hydrogels, and thereby potentially influencing the ability for HUVECs to self-assemble<sup>6</sup>.

48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

The extrusion-based bioprinting of complex cell-laden constructs poses the challenge of formulating a cell-friendly hydrogel with low stiffness, that, at the same time, displays high shape fidelity after printing<sup>44–46</sup>. Because the filament collapse test showed that the bioinks were unable to form a stable filament upon conventional extrusion, and thus failed to bridge gaps of  $\geq 1$  mm, the bioinks were printed into a gellan gum microgel support bath. The microgel slurry provided a sufficient support to enable free-form fabrication of suspended filaments of any length that experience no collapse or gravity-induced deformation. Previous works in the field of suspended bath printing have demonstrated that higher printing resolutions and low

1  
2  
3 surface roughness of the filament can be achieved by using smooth, spherical-shaped  
4 microgels, and by decreasing microgel size and polydispersity<sup>47,48</sup>. Even so, printing resolution  
5 and shape fidelity are also dependent on the rapid gelation of the bioink upon contact with the  
6 suspension bath, limiting the percolation of the ink into the space in between microgels. As a  
7 consequence, constructs with filament size as low as 20  $\mu\text{m}$  have been obtained with limited  
8 classes of materials, such as ionically crosslinked alginates or collagen inks prepared at  
9 collagen concentrations significantly higher (24 mg mL<sup>-1</sup>) compared to what conventionally  
10 used for the culture of encapsulated cells<sup>48</sup>. Conversely, the printing settings and microgel  
11 bath compositions identified in this study enabled to effectively print fibers with diameters in  
12 the range of  $440 \pm 70 \mu\text{m}$ , even with these fibrin inks with low mechanical properties. Such  
13 low-polymer content structure was proven suitable to permit cell proliferation and migration,  
14 which are needed to sustain angiogenesis from HUVEC and MSC co-cultures, leading to rapid  
15 neo-capillary formation within two days after printing.  
16  
17

18  
19  
20  
21  
22  
23  
24  
25 The two formulated bioinks were used to 3D-print a complex meniscus-shaped  
26 construct, with an outer vascularized and inner non-vascularized zone. The outer zone was  
27 created using the pro-angiogenic bioink, and the inner zone was composed of the anti-  
28 angiogenic bioink with encapsulated MPCs, representing fibrochondrocytes and fibroblast-like  
29 cells that are normally present in the inner zone<sup>49</sup>. After 14 days, successful formation of  
30 HUVEC-driven networks was visible, including a separated inner and outer zone, and the  
31 presence of open lumen-like structures in the middle of a six mm high 3D bioprinted construct.  
32  
33

34  
35  
36 HUVEC-driven network formation is highly dependent on the presence of selected  
37 growth factors, that allow single endothelial cells to self-assemble in to capillary-like structures,  
38 and supporting cells to become pericytes. Yet, inducing MCs and MPCs to commit into a  
39 (fibro)chondrogenic lineage, requires a different set of media supplements<sup>29</sup>, which can  
40 potentially interfere with the commitment of MSCs to differentiate into pericytes, as well as  
41 with endothelial cells to function. To the best of our knowledge, an optimized co-culture of  
42 endothelial cells with MSCs, and meniscus (progenitor) cells has not been reported before. In  
43 previous studies, co-cultures of HUVECs with MCs were only performed in endothelial cell  
44 culture medium, to assess MC migration, with no provided insight on the impact of this medium  
45 formulation on MC and MPC matrix deposition<sup>47</sup>. Co-cultures of pre-vascularized osteogenic  
46 constructs, instead, have been setup with success, allowing the formation of endothelial cell-  
47 based networks and differentiation of MSCs into the osteogenic lineage, even with osteogenic  
48 medium alone<sup>5,50</sup>.  
49  
50  
51  
52  
53  
54  
55  
56

57  
58 In this study, HUVEC-driven networks formed successfully when cultured in EGM-2  
59 medium, but failed in presence of  $\geq 25\%$  v/v chondrogenic differentiation medium with TGF-  
60



1  
2  
3  $\beta 1$ , whereas the meniscus (progenitor) cells expressed type I collagen only in presence of  $\geq$   
4 25% v/v. This suggests that other cell culture medium conditions are required to promote  
5 microvessel formation and meniscus (progenitor) cell matrix deposition in the same construct.  
6 Since the collapse of HUVEC-driven networks in presence of chondrogenic differentiation  
7 medium growth factors may be explained by the failure of MSCs to differentiate into pericytes,  
8 we investigated the use of a temporal switch of cell culture medium. We found that an initial  
9 7-day culture period in EGM-2, followed by 7 days in 10 or 25% v/v chondrogenic  
10 differentiation medium facilitated both a stable HUVEC-driven network, as well as the  
11 expression of type I collagen by MPCs. Thus, while the initial presence of chondrogenic  
12 differentiation medium prevents the building of a stable capillary network, the introduction of  
13 the same formulation at a later stage during culture, results in the preservation of the stability  
14 of the vessels. This indicates that the HUVEC-MSCs are sensitive to the timing of presented  
15 media supplements, which can be a useful starting point for setting up co-culture conditions  
16 for other tissue-specific cells with microvessels. In addition, although our data suggests that  
17 TGF- $\beta 1$  supplementation in the second week of culture can impair vessel formation and  
18 stability, this same negative effect was not observed when this growth factor was added to  
19 EGM-2 together with 25% of the complete chondrogenic media. This underlines how different  
20 components in the media, besides the main growth factors, can significantly influence cell  
21 behavior.  
22

23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35 In terms of fibrocartilage neo-synthesis, while the inner meniscal zone consists of both  
36 type I and II collagen, we found little to no type II collagen deposition. Similarly, no  
37 proteoglycan deposition was seen by any of the meniscus (progenitor) cells, in none of the  
38 medium conditions. It was, however, shown before that the MPCs used in this study can  
39 transcribe COL2A1 and ACAN mRNA, and express small amounts of type II collagen and  
40 proteoglycans, observed by respectively immunohistochemistry and histochemistry<sup>29</sup>. The  
41 absence or limited deposition of type II collagen, and GAGs in this study could be explained  
42 by the shorter culture time of 14 days compared to 28 days, or the use of a fibrin gel instead  
43 of a pellet culture, influencing the MPC cell density, and thereby potentially their growth and  
44 differentiation potential. It should be noted that, proteoglycan levels in the human inner  
45 meniscal zone are generally much lower than articular cartilage and comprise less than 1% of  
46 a meniscus wet weight<sup>51</sup>. Moreover, proteoglycan levels increase with age and (initially) with  
47 progress of degenerative pathologies<sup>51,52</sup>. The MPCs in this study are derived from adult  
48 donors with OA menisci, which may be the explanation for the potential of the MPCs to  
49 produce GAGs<sup>29</sup>.  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 We also observed type I collagen deposition in the large 3D bioprinted structures (6  
4 mm high), composed of the pro-angiogenic and anti-angiogenic bioink. The culture medium  
5 composition included a temporal switch to a partial chondrogenic differentiation medium  
6 formulation after 7 days, which we demonstrated to be effective for MPC-mediated type I  
7 collagen deposition in fibrin gels (Figure 4(b)). Within the non-vascularized MPC-laden zone,  
8 type I collagen staining was especially marked in regions closer to the edge of the construct,  
9 and with noticeably lower intensity at locations in the middle of the constructs after 14 days of  
10 culture. The intensity of the staining, indicative of type I collagen abundance was, expectedly,  
11 lower in the 6 mm-high 3D bioprinted construct compared the 20  $\mu$ L fibrin gels loaded with  
12 MPCs. Due to the diffusion limit of nutrients and gasses across longer distances in cell-laden  
13 constructs and tissues, cells located further away from a capillary network, or, *in vitro* settings  
14 from the direct contact with the culture media, may receive a lower number of metabolites,  
15 which can lead to reduced matrix biosynthesis. Consistently, this behavior was also observed  
16 in our large bioprinted block-shaped constructs with dimensions of 10.8 x 7.2 x 6.0 mm (L x D  
17 x H). Considering the size of the construct and culturing in a static condition, it is likely that  
18 cells too far away from the medium were cultured under limited nutritional conditions. Dynamic  
19 culture strategies (i.e. involving automated exchange of media or the use of bioreactors)  
20 together with enhanced porosity introduced by 3D printing strategies could address such  
21 challenges<sup>52</sup>. In the vascularized zone of the large 3D bioprinted construct, type I collagen  
22 deposition was abundantly visible around stretched areas containing open lumen-like  
23 structures most likely part of an immature capillary network. We already observed that the  
24 small fibrin hydrogels-laden with endothelial and mural cells allowed the growth of capillary  
25 structures with open lumen after 14 days of culture. We here show that also in the formulated  
26 bioink, consisting of fibrin gel and col-1 MFs, such structures form, even in the middle of a  
27 larger bioprinted construct. It is possible that the porosity of the bioprinted construct introduced  
28 by the distance between printed filaments, allows the diffusion of media components, and thus  
29 contributes to the formation of HUVEC-mediated capillary-like structures.  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47

48 While providing an important proof of concept and generalizable strategies to modulate  
49 angiogenesis in printed constructs with the help of ECM-derived MFs, this study has several  
50 limitations. First, the col-1, col-2, and CdECM MFs are derived from different species: bovine,  
51 chick, and equine. While the isolated col-1 and col-2 sponges and the CdECM should be  
52 deprived from cellular materials, the MFs may harbor species-specific moieties, that could not  
53 be identified in this study, and that could influence the behavior of the human-derived  
54 HUVECs, MSCs, and MPCs, compared to if the MFs were derived from the same species or  
55 individual. Still, the availability of post-mortem healthy human tissues is limited compared to  
56  
57  
58  
59  
60

1  
2  
3 animal tissues, posing extra challenges when choosing to use allogeneic or autologous,  
4 instead of xenogeneic tissue products. Second, in order to bring cell-laden tissue engineered  
5 constructs into the clinic, it is of importance to consider which cell types and sources should  
6 ideally be used. The MPCs used in this study are derived from menisci of osteoarthritic knee  
7 joints, meaning that they have resided in an inflamed environment prior to their isolation. While  
8 such cells were shown to express differential gene expression patterns and surface markers,  
9 such as CD318, compared to cells derived from healthy menisci, it has also been shown that  
10 the expression patterns comparable to those of MPCs derived from healthy menisci can be  
11 recovered upon *in vitro* expansion in culture media supplied with TGF $\beta$ 1<sup>53</sup>. Furthermore,  
12 rejection of implanted tissue equivalents must be avoided, hence autologous primary, or iPSC-  
13 derived cells are preferred over allogeneic cell sources. This, however, brings up the challenge  
14 of donor-variability, meaning that cells that are isolated from different individuals do not  
15 perform in a similar way<sup>5</sup>. Within the scope of this study, one donor per cell type was used for  
16 the experiments, where both the MSCs and MPCs are primary cells derived from human  
17 patients. In future studies, also patient-derived endothelial cells could be implemented to  
18 improve the study's translational perspectives. Additionally, fibrinogen and thrombin are  
19 bovine-derived, and may therefore be less clinically translatable, compared to human  
20 fibrinogen and thrombin. Since fibrinogen is highly conserved between species, except for the  
21  $\alpha$ -carboxy region, the origin may have an influence on material (mechanical) properties after  
22 crosslinking<sup>54-56</sup>. Nevertheless, the implementation of fibrin from different sources should  
23 always be optimized within future studies. Another challenge is the co-culture of different cell  
24 types in one tissue construct. We demonstrated that the co-culture of HUVECs, MSCs, and  
25 MPCs by simple mixture of cell culture media does not provide a suitable environment to  
26 stimulate HUVEC-driven capillary formation, the differentiation of MSCs into pericytes, and at  
27 the same time the differentiation of MPCs. For this setup we found a solution in the temporal  
28 switching of medium composition. Still, to further facilitate optimal functionality of different cell  
29 types in a co-culture, additional solutions need to be sought, for example, the local  
30 incorporation of bioactive molecules strong enough to steer cell differentiation locally. Finally,  
31 in light of future applications for meniscus replacement strategies, the constructs produced in  
32 this study would need to be reinforced with adequate supporting materials, to match the  
33 mechanical properties of native menisci. Elegant strategies for mechanical reinforcement of  
34 bioprinted hydrogels have been thoroughly described in the literature by co-printing or (melt)  
35 electrowriting of thermoplastic polymers<sup>57-64</sup>. While these may be complex to perform in  
36 presence of suspended baths, alternative and effective strategies may involve the co-printing  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 with supporting strong hydrogels<sup>65,66</sup>, which would not require major engineering efforts to be  
4 printed in particular media.  
5

6  
7 Moreover, the versatile strategy proposed in this study introduces new opportunities  
8 to exploit the biological response to ECM-derived MFs, in order to steer the fate and bioactivity  
9 of the bioprinted cells. MFs derived from a broader range of tissues or matrix components  
10 could be used as bioink supplement, and their geometrical and topographical features could  
11 be exploited as well, for instance to induce cell alignment in response to MF orientation, which  
12 could be modulated by the shear stresses produced by the printing process, or via the  
13 application of external stimuli (i.e., magnetic field for fibers functionalized with  
14 magneto-responsive compounds<sup>67,68</sup>.  
15  
16  
17  
18  
19

20 In summary, we present pro- and anti-angiogenic fibrin-based biomaterials that can be  
21 combined with cells and printed into complex shapes, as was presented here by bioprinting a  
22 meniscus construct with a vascularized and non-vascularized zone as a proof of concept.  
23 These bioinks can be utilized for the spatial control of capillary formation in a 3D construct,  
24 and the recreation of anisotropic tissue constructs with embedded prevascular capillary  
25 networks. With the use of col-1 and CdECM MF, the angiogenic capacity of the bioinks can  
26 be easily adjusted, without the need for chemical modification of the ink. These versatile  
27 bioinks can further be used for *in vitro* models for drug testing or studying mechanisms of  
28 angiogenesis.  
29  
30  
31  
32  
33  
34  
35

### 36 Ethical statement

37  
38 Meniscus tissue was collected according to the Medical Ethics regulations of the  
39 University Medical Center Utrecht and the guideline “Human Tissue and Medical Research:  
40 Code of Conduct for responsible use” of the Dutch Federation of Medical Research Societies.  
41 Human bone marrow was isolated from the iliac crest of patients after their informed consent,  
42 when receiving spondylodesis or hip replacement surgery. Isolation and distribution were  
43 performed in accordance with protocols approved by the Biobank Research Ethics Committee  
44 (isolation 08-001, distribution protocol 18-739, University Medical Center Utrecht). Protocols  
45 used are in line with the principles embodied in the Declaration of Helsinki.  
46  
47  
48  
49  
50  
51  
52

### 53 Acknowledgements

54  
55 The authors acknowledge Liu Hao, Leanne de Silva, Margot Rijkers, and Jasmijn  
56 Korpershoek for their help with the HUVEC co-culture and for providing MSCs, MCs and  
57 MPCs. This project has received funding from the European Research Council (ERC) under  
58 the European Union’s Horizon 2020 research and innovation programme (grant agreement  
59  
60

No. 949806, No. 647426, and No. 814444). The authors acknowledge funding from ReumaNederland (LLP-12 and 22), and R.L. acknowledges support from to the 2019 Hofvijverkring Fellowship. The authors also acknowledge financial support by Mirai-Program (21-201031456) from JST and Grant-in-Aid for Scientific Research (A) (20H00665) from JSPS. The antibody against collagen type II, developed by T. F. Linsenmayer, was obtained from the Developmental Studies Hybridoma Bank, created by the NICHD and maintained at The University of Iowa, Department of Biology, Iowa City, IA 52242.

## References

- (1) Groll, J.; Boland, T.; Blunk, T.; Burdick, J. A.; Cho, D. W.; Dalton, P. D.; Derby, B.; Forgacs, G.; Li, Q.; Mironov, V. A.; Moroni, L.; Nakamura, M.; Shu, W.; Takeuchi, S.; Vozzi, G.; Woodfield, T. B. F.; Xu, T.; Yoo, J. J.; Malda, J. Biofabrication: Reappraising the Definition of an Evolving Field. *Biofabrication* **2016**, *8* (1). <https://doi.org/10.1088/1758-5090/8/1/013001>.
- (2) Datta, P.; Ayan, B.; Ozbolat, I. T. Bioprinting for Vascular and Vascularized Tissue Biofabrication. *Acta Biomaterialia* **2017**, *51*, 1–20. <https://doi.org/10.1016/j.actbio.2017.01.035>.
- (3) Kolesky, D. B.; Homan, K. A.; Skylar-Scott, M. A.; Lewis, J. A. Three-Dimensional Bioprinting of Thick Vascularized Tissues. *Proceedings of the National Academy of Sciences of the United States of America* **2016**, *113* (12), 3179–3184. <https://doi.org/10.1073/pnas.1521342113>.
- (4) Ouyang, L.; Armstrong, J. P. K.; Chen, Q.; Lin, Y.; Stevens, M. M. Void-Free 3D Bioprinting for In Situ Endothelialization and Microfluidic Perfusion. *Advanced Functional Materials* **2020**, *30* (1). <https://doi.org/10.1002/adfm.201908349>.
- (5) Pennings, I.; van Dijk, L. A.; van Huuksloot, J.; Fledderus, J. O.; Schepers, K.; Braat, A. K.; Hsiao, E. C.; Barruet, E.; Morales, B. M.; Verhaar, M. C.; Rosenberg, A. J. W. P.; Gawlitta, D. Effect of Donor Variation on Osteogenesis and Vasculogenesis in Hydrogel Cocultures. *Journal of Tissue Engineering and Regenerative Medicine* **2019**, *13* (3), 433–445. <https://doi.org/10.1002/term.2807>.
- (6) Liu, H.; Kitano, S.; Irie, S.; Levato, R.; Matsusaki, M. Collagen Microfibers Induce Blood Capillary Orientation and Open Vascular Lumen. *Advanced Biosystems* **2020**, *4* (5). <https://doi.org/10.1002/adbi.202000038>.
- (7) Evensen, L.; Micklem, D. R.; Blois, A.; Berge, S. V.; Aarsaether, N.; Littlewood-Evans, A.; Wood, J.; Lorens, J. B. Mural Cell Associated VEGF Is Required for Organotypic

- 1  
2  
3 Vessel Formation. *PLoS ONE* **2009**, 4 (6).  
4 <https://doi.org/10.1371/journal.pone.0005798>.  
5  
6 (8) Verdonk, P. C. M.; Forsyth, R. G.; Wang, J.; Almquist, K. F.; Verdonk, R.; Veys, E. M.;  
7 Verbruggen, G. Characterisation of Human Knee Meniscus Cell Phenotype.  
8 *Osteoarthritis and Cartilage* **2005**, 13 (7), 548–560.  
9 <https://doi.org/10.1016/j.joca.2005.01.010>.  
10  
11 (9) Fournier, D. E.; Kiser, P. K.; Shoemaker, J. K.; Battié, M. C.; Séguin, C. A.  
12 Vascularization of the Human Intervertebral Disc: A Scoping Review. *JOR Spine* **2020**,  
13 3 (4). <https://doi.org/10.1002/jsp2.1123>.  
14  
15 (10) Bonnet, C. S.; Walsh, D. A. Osteoarthritis, Angiogenesis and Inflammation.  
16 *Rheumatology* **2005**, 44 (1), 7–16. <https://doi.org/10.1093/rheumatology/keh344>.  
17  
18 (11) Bilgen, B.; Jayasuriya, C. T.; Owens, B. D. Current Concepts in Meniscus Tissue  
19 Engineering and Repair. **2018**, 7 (11).  
20 <https://doi.org/10.1002/adhm.201701407>. Current.  
21  
22 (12) Arnoczky, S. P.; Warren, R. F. Microvasculature of the Human Meniscus. *The American*  
23 *Journal of Sports Medicine* **1982**, 10 (2), 90–95.  
24 <https://doi.org/10.1177/036354658201000205>.  
25  
26 (13) Freemont, A. J.; Peacock, T. E.; Goupille, P.; Hoyland, J. A.; O'Brien, J.; Jayson, M. I.  
27 V. Nerve Ingrowth into Diseased Intervertebral Disc in Chronic Back Pain. *Lancet* **1997**,  
28 350 (9072), 178–181. [https://doi.org/10.1016/S0140-6736\(97\)02135-1](https://doi.org/10.1016/S0140-6736(97)02135-1).  
29  
30 (14) Mapp, P. I.; Walsh, D. A. Mechanisms and Targets of Angiogenesis and Nerve Growth  
31 in Osteoarthritis. *Nature Reviews Rheumatology* **2012**, 8, 390–398.  
32 <https://doi.org/10.1038/nrrheum.2012.80>.  
33  
34 (15) Ashraf, S.; Wibberley, H.; Mapp, P. I.; Hill, R.; Wilson, D.; Walsh, D. A. Increased  
35 Vascular Penetration and Nerve Growth in the Meniscus: A Potential Source of Pain in  
36 Osteoarthritis. *Annals of the Rheumatic Diseases* **2011**, 70 (3), 523–529.  
37 <https://doi.org/10.1136/ard.2010.137844>.  
38  
39 (16) Freemont, A. J.; Watkins, A.; le Maitre, C.; Baird, P.; Jeziorska, M.; Knight, M. T. N.;  
40 Ross, E. R. S.; O'Brien, J. P.; Hoyland, J. A. Nerve Growth Factor Expression and  
41 Innervation of the Painful Intervertebral Disc. *Journal of Pathology* **2002**, 197, 286–292.  
42 <https://doi.org/10.1002/path.1108>.  
43  
44 (17) Pulsatelli, L.; Dolzani, P.; Silvestri, T.; Frizziero, L.; Facchini, A.; Meliconi, R. Vascular  
45 Endothelial Growth Factor Activities on Osteoarthritic Chondrocytes. *Clinical and*  
46 *Experimental Rheumatology* **2005**, 23 (4), 487–493.  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
- (18) Casanova, M. R.; Oliveira, C.; Fernandes, E. M.; Reis, R. L.; Silva, T. H.; Martins, A.; Neves, N. M. Spatial Immobilization of Endogenous Growth Factors to Control Vascularization in Bone Tissue Engineering. *Biomaterials Science* **2020**, *8* (9), 2577. <https://doi.org/10.1039/d0bm00087f>.
- (19) Zheng, L.; Ling, P.; Wang, Z.; Niu, R.; Hu, C.; Zhang, T.; Lin, X. A Novel Polypeptide from Shark Cartilage with Potent Anti-Angiogenic Activity. *Cancer Biology and Therapy* **2007**, *6* (5), 775–780. <https://doi.org/10.4161/cbt.6.5.4002>.
- (20) Bargahi, A.; Rabbani-Chadegani, A. Angiogenic Inhibitor Protein Fractions Derived from Shark Cartilage. *Bioscience Reports* **2008**, *28* (1), 15–21. <https://doi.org/10.1042/BSR20070029>.
- (21) Toyono, T.; Usui, T.; Yokoo, S.; Taketani, Y.; Nakagawa, S.; Kuroda, M.; Yamagami, S.; Amano, S. Angiopoietin-like 7 Is an Anti-Angiogenic Protein Required to Prevent Vascularization of the Cornea. *PLoS ONE* **2015**, *10* (1). <https://doi.org/10.1371/journal.pone.0116838>.
- (22) Pufe, T.; Petersen, W. J.; Miosge, N.; Goldring, M. B.; Mentlein, R.; Varoga, D. J.; Tillmann, B. N. Endostatin/Collagen XVIII - An Inhibitor of Angiogenesis - Is Expressed in Cartilage and Fibrocartilage. *Matrix Biology* **2004**, *23* (5), 267–276. <https://doi.org/10.1016/j.matbio.2004.06.003>.
- (23) Yue, L.; Shen, Y. X.; Feng, L. J.; Chen, F. H.; Yao, H. W.; Liu, L. H.; Wu, Q.; Wang, H. Blockage of the Formation of New Blood Vessels by Recombinant Human Endostatin Contributes to the Regression of Rat Adjuvant Arthritis. *European Journal of Pharmacology* **2007**, *567* (1–2), 166–170. <https://doi.org/10.1016/j.ejphar.2007.03.057>.
- (24) Cornejo, M. C.; Cho, S. K.; Giannarelli, C.; Iatridis, J. C.; Purmessur, D. Soluble Factors from the Notochordal-Rich Intervertebral Disc Inhibit Endothelial Cell Invasion and Vessel Formation in the Presence and Absence of pro-Inflammatory Cytokines. *Osteoarthritis and Cartilage* **2015**, *23* (3), 487–496. <https://doi.org/10.1016/j.joca.2014.12.010>.
- (25) Choi, B. H.; Choi, K. H.; Lee, H. S.; Song, B. R.; Park, S. R.; Yang, J. W.; Min, B. H. Inhibition of Blood Vessel Formation by a Chondrocyte-Derived Extracellular Matrix. *Biomaterials* **2014**, *35* (22), 5711–5720. <https://doi.org/10.1016/j.biomaterials.2014.03.083>.
- (26) Li, J.; Sasaki, N.; Itaka, K.; Terpstra, M.; Levato, R.; Matsusaki, M. Regulation of Chondrocyte Differentiation by Changing Intercellular Distances Using Type II Collagen Microfibers. *ACS Biomaterials Science and Engineering* **2020**, *6* (10), 5711–5719. <https://doi.org/10.1021/acsbomaterials.0c00427>.

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
- (27) Benders, K. E. M. M.; Boot, W.; Cokelaere, S. M.; van Weeren, P. R.; Gawlitta, D.; Bergman, H. J.; Saris, D. B. F. F.; Dhert, W. J. A. A.; Malda, J. Multipotent Stromal Cells Outperform Chondrocytes on Cartilage-Derived Matrix Scaffolds. *Cartilage* **2014**, *5* (4), 221–230. <https://doi.org/10.1177/1947603514535245>.
- (28) Pittenger, B.; Erina, N.; Su, C. J. A. N. V. I. I. Quantitative Mechanical Property Mapping at the Nanoscale with PeakForce QNM. **2010**, *1*, 1–11.
- (29) Korpershoek, J. v; Rijkers, M.; Windt, T. S. de; Tryfonidou, M. A.; Saris, D. B. F.; Vonk, L. A. Selection of Highly Proliferative and Multipotent Meniscus Progenitors through Differential Adhesion to Fibronectin: A Novel Approach in Meniscus Tissue Engineering. *International Journal of Molecular Sciences* **2021**, *22*.
- (30) Ouyang, L.; Armstrong, J. P. K. J. P. K.; Lin, Y.; Wojciechowski, J. P. J. P.; Lee-Reeves, C.; Hachin, D.; Zhou, K.; Burdick, J. A.; Stevens, M. M. M. M.; Hachim, D.; Zhou, K.; Burdick, J. A.; Stevens, M. M. M. M. Expanding and Optimizing 3D Bioprinting Capabilities Using Complementary Network Bioinks. *Science Advances* **2020**, No. September, 1–14. [https://doi.org/10.1126/SCIADV.ABC5529/SUPPL\\_FILE/ABC5529\\_SM.PDF](https://doi.org/10.1126/SCIADV.ABC5529/SUPPL_FILE/ABC5529_SM.PDF).
- (31) Zudaire, E.; Gambardella, L.; Kurcz, C.; Vermeren, S. A Computational Tool for Quantitative Analysis of Vascular Networks. *PLoS ONE* **2011**, *6* (11). <https://doi.org/10.1371/journal.pone.0027385>.
- (32) Ribeiro, A.; Blokzijl, M. M.; Levato, R.; Visser, C. W.; Castilho, M.; Hennink, W. E.; Vermonden, T.; Malda, J. Assessing Bioink Shape Fidelity to Aid Material Development in 3D Bioprinting. *Biofabrication* **2018**, *10*. <https://doi.org/10.1088/1758-5090/aa90e2>.
- (33) Gautieri, A.; Vesentini, S.; Redaelli, A.; Buehler, M.J. Hierarchical Structure and Nanomechanics of Collagen Microfibrils from the Atomistic Scale Up. *Nano letters* **2011**, *11* (2), 757–766. <https://doi.org/10.1021/NL103943U>.
- (34) Brézillon, S.; Untereiner, V.; Mohamed, H. T.; Hodin, J.; Chatron-Colliet, A.; Maquart, F.-X.; Sockalingum, G. D. Probing Glycosaminoglycan Spectral Signatures in Live Cells and Their Conditioned Media by Raman Microspectroscopy. *Analyst* **2017**, *142* (8), 1333–1341. <https://doi.org/10.1039/C6AN01951J>.
- (35) Zhang, Q.; Chan, K. L. A.; Zhang, G.; Gillece, T.; Senak, L.; Moore, D. J.; Mendelsohn, R.; Flach, C. R. Raman Microspectroscopic and Dynamic Vapor Sorption Characterization of Hydration in Collagen and Dermal Tissue. *Biopolymers* **2011**, *95* (9), 607–615. <https://doi.org/10.1002/BIP.21618>.
- (36) Lee, A.; Hudson, A. R.; Shiwerski, D. J.; Tashman, J. W.; Hinton, T. J.; Yerneni, S.; Bliley, J. M.; Campbell, P. G.; Feinberg, A. W. 3D Bioprinting of Collagen to Rebuild

- 1  
2  
3 Components of the Human Heart. *Science* **2019**, *365* (6452), 482–487.  
4 <https://doi.org/10.1126/science.aav9051>.  
5  
6 (37) Seong Kim, D.; Woo Lee, M.; Jong Ko, Y.; Hoon Chun, Y.; Joon Kim, H.; Woong Sung,  
7 K.; Hoe Koo, H.; Hee Yoo, K. Cell Culture Density Affects the Proliferation Activity of  
8 Human Adipose Tissue Stem Cells. **2016**. <https://doi.org/10.1002/cbf.3158>.  
9  
10 (38) MS, B.; JP, S.-P.; GS, O.; PA, P.; MB, A.; JL, P.; ML, O.; MM, S. Raman Spectroscopy  
11 Reveals New Insights into the Zonal Organization of Native and Tissue-Engineered  
12 Articular Cartilage. *ACS central science* **2016**, *2* (12), 885–895.  
13 <https://doi.org/10.1021/ACSCENTSCI.6B00222>.  
14  
15 (39) Power, L. J.; Fasolato, C.; Barbero, A.; Wendt, D. J.; Wixmerten, A.; Martin, I.; Asnaghi,  
16 M. A. Sensing Tissue Engineered Cartilage Quality with Raman Spectroscopy and  
17 Statistical Learning for the Development of Advanced Characterization Assays.  
18 *Biosensors & bioelectronics* **2020**, *166*. <https://doi.org/10.1016/J.BIOS.2020.112467>.  
19  
20 (40) Bergholt, M. S.; St-Pierre, J. P.; Offeddu, G. S.; Parmar, P. A.; Albro, M. B.; Puetzer, J.  
21 L.; Oyen, M. L.; Stevens, M. M. Raman Spectroscopy Reveals New Insights into the  
22 Zonal Organization of Native and Tissue-Engineered Articular Cartilage. *ACS Central*  
23 *Science* **2016**, *2* (12), 885–895. <https://doi.org/10.1021/acscentsci.6b00222>.  
24  
25 (41) Kobayashi, T.; Kakizaki, I.; Nozaka, H.; Nakamura, T. Chondroitin Sulfate  
26 Proteoglycans from Salmon Nasal Cartilage Inhibit Angiogenesis. *Biochemistry and*  
27 *Biophysics Reports* **2017**, *9*, 72–78. <https://doi.org/10.1016/j.bbrep.2016.11.009>.  
28  
29 (42) Yun, H. W.; Choi, B. H.; Park, D. Y.; Jin, L. H.; Min, B. H. Inhibitory Effect of Topical  
30 Cartilage Acellular Matrix Suspension Treatment on Neovascularization in a Rabbit  
31 Corneal Model. *Tissue Engineering and Regenerative Medicine* **2020**, *17* (5), 625–640.  
32 <https://doi.org/10.1007/s13770-020-00275-3>.  
33  
34 (43) Sandell, L. J. Novel Functions for Type II Procollagen. *Connective Tissue Research*  
35 **2014**, *55* (1), 20–25. <https://doi.org/10.3109/03008207.2013.867340>.  
36  
37 (44) Schwab, A.; Levato, R.; D'este, M.; Piluso, S.; Eglin, D.; Malda, J. Printability and Shape  
38 Fidelity of Bioinks in 3D Bioprinting. *Chemical Reviews* **2020**, *120*, 11028–11055.  
39 <https://doi.org/10.1021/acs.chemrev.0c00084>.  
40  
41 (45) Levato, R.; Jungst, T.; Scheuring, R. G.; Blunk, T.; Groll, J.; Malda, J. From Shape to  
42 Function: The Next Step in Bioprinting. *Advanced Materials* **2020**, *32* (12).  
43 <https://doi.org/10.1002/adma.201906423>.  
44  
45 (46) Malda, J.; Visser, J.; Melchels, F. P.; Jüngst, T.; Hennink, W. E.; Dhert, W. J. A.; Groll,  
46 J.; Hutmacher, D. W. 25th Anniversary Article: Engineering Hydrogels for  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 Biofabrication. *Advanced Materials* **2013**, *25* (36), 5011–5028.  
4 <https://doi.org/10.1002/adma.201302042>.  
5  
6 (47) Hinton, T. J.; Jallerat, Q.; Palchesko, R. N.; Park, J. H.; Grodzicki, M. S.; Shue, H. J.;  
7 Ramadan, M. H.; Hudson, A. R.; Feinberg, A. W. Three-Dimensional Printing of  
8 Complex Biological Structures by Freeform Reversible Embedding of Suspended  
9 Hydrogels. *Science Advances* **2015**, *1* (9), 1–10.  
10 <https://doi.org/10.1126/sciadv.1500758>.  
11  
12 (48) Lee, A.; Hudson, A. R.; Shiwardski, D. J.; Tashman, J. W.; Hinton, T. J.; Yerneni, S.;  
13 Bliley, J. M.; Campbell, P. G.; Feinberg, A. W. 3D Bioprinting of Collagen to Rebuild  
14 Components of the Human Heart. *Science* **2019**, *365* (6452), 482–487.  
15 <https://doi.org/10.1126/science.aav9051>.  
16  
17 (49) Cengiz, I. F.; Pereira, H.; Pêgo, J. M.; Sousa, N.; Espregueira-Mendes, J.; Oliveira, J.  
18 M.; Reis, R. L. Segmental and Regional Quantification of 3D Cellular Density of Human  
19 Meniscus from Osteoarthritic Knee. *Journal of Tissue Engineering and Regenerative*  
20 *Medicine* **2017**, *11* (6), 1844–1852. <https://doi.org/10.1002/term.2082>.  
21  
22 (50) Bernal, P. N.; Delrot, P.; Loterie, D.; Li, Y.; Malda, J.; Moser, C.; Levato, R. Volumetric  
23 Bioprinting of Complex Living-Tissue Constructs within Seconds. *Advanced Materials*  
24 **2019**, *31* (42). <https://doi.org/10.1002/adma.201904209>.  
25  
26 (51) López-Franco, M.; Gómez-Barrena, E. Cellular and Molecular Meniscal Changes in the  
27 Degenerative Knee: A Review. *Journal of Experimental Orthopaedics* **2018**, *5* (1).  
28 <https://doi.org/10.1186/s40634-018-0126-8>.  
29  
30 (52) Ying, G.-L.; Jiang, N.; Maharjan, S.; Yin, Y.-X.; Chai, R.-R.; Cao, X.; Yang, J.-Z.; Miri,  
31 A. K.; Hassan, S.; Shrike Zhang, Y.; Ying, G.; Maharjan, S.; Yin, Y.; Chai, R.; Cao, X.;  
32 Yang, J.; Miri, A. K.; Hassan, S.; Zhang, Y. S.; Jiang, B. N. Aqueous Two-Phase  
33 Emulsion Bioink-Enabled 3D Bioprinting of Porous Hydrogels. *Advanced Materials*  
34 **2018**, *30* (50), 1805460. <https://doi.org/10.1002/ADMA.201805460>.  
35  
36 (53) Sun, H.; Wen, X.; Li, H.; Wu, P.; Gu, M.; Zhao, X.; Zhang, Z. Z.; Hu, S.; Mao, G.; Ma,  
37 R.; Liao, W.; Zhang, Z. Z. Single-Cell RNA-Seq Analysis Identifies Meniscus  
38 Progenitors and Reveals the Progression of Meniscus Degeneration. *Annals of the*  
39 *Rheumatic Diseases* **2019**, 408–417. [https://doi.org/10.1136/annrheumdis-2019-](https://doi.org/10.1136/annrheumdis-2019-215926)  
40 [215926](https://doi.org/10.1136/annrheumdis-2019-215926).  
41  
42 (54) Falvo, M. R.; Gorkun, O. v.; Lord, S. T. The Molecular Origins of the Mechanical  
43 Properties of Fibrin. *Biophysical Chemistry* **2010**, *152* (1–3), 15–20.  
44  
45 (55) Okude, M.; Sadaaki Iwanaga, A. Carboxyl-Terminal Residues of Mammalian  
46 Fibrinogen and Fibrin. *Biochimica et Biophysica Acta* **1971**, *251*, 185–196.  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
- (56) Falvo, M. R.; Millard, D.; O'Brien, E. T.; Superfine, R.; Lord, S. T. Length of Tandem Repeats in Fibrin's AC Region Correlates with Fiber Extensibility. *Journal of thrombosis and haemostasis: JTH* **2008**, *6* (11), 1991–1993. <https://doi.org/10.1111/J.1538-7836.2008.03147.X>.
- (57) Schuurman, W.; Khristov, V.; Pot, M. W.; van Weeren, P. R.; Dhert, W. J. A.; Malda, J. Bioprinting of Hybrid Tissue Constructs with Tailorable Mechanical Properties. *Biofabrication* **2011**, *3* (2). <https://doi.org/10.1088/1758-5082/3/2/021001>.
- (58) Mouser, V. H. M.; Abbadessa, A.; Levato, R.; Hennink, W. E.; Vermonden, T.; Gawlitta, D.; Malda, J. Development of a Thermosensitive HAMA-Containing Bio-Ink for the Fabrication of Composite Cartilage Repair Constructs. *Biofabrication* **2017**, *9* (1), 1–24. <https://doi.org/10.1088/1758-5090/aa6265>.
- (59) Pati, F.; Jang, J.; Ha, D. H.; Won Kim, S.; Rhie, J. W.; Shim, J. H.; Kim, D. H.; Cho, D. W. Printing Three-Dimensional Tissue Analogues with Decellularized Extracellular Matrix Bioink. *Nature Communications* **2014**, *5*, 1–11. <https://doi.org/10.1038/ncomms4935>.
- (60) Diloksumpan, P.; de Ruijter, M.; Castilho, M.; Gbureck, U.; Vermonden, T.; van Weeren, P. R.; Malda, J.; Levato, R. Combining Multi-Scale 3D Printing Technologies to Engineer Reinforced Hydrogel-Ceramic Interfaces. *Biofabrication* **2020**, *12* (2), 025014. <https://doi.org/10.1088/1758-5090/ab69d9>.
- (61) Nam, H.; Jeong, H.-J.; Jo, Y.; Lee, J. Y.; Ha, D.-H.; Kim, J. H.; Chung, J. H.; Cho, Y.-S.; Cho, D.-W.; Lee, S.-J.; Jang, J. Multi-Layered Free-Form 3D Cell-Printed Tubular Construct with Decellularized Inner and Outer Esophageal Tissue-Derived Bioinks. *Scientific Reports* **2020**, *10* (1), 7255. <https://doi.org/10.1038/s41598-020-64049-6>.
- (62) Guo, W.; Chen, M.; Wang, Z. Z.; Tian, Y.; Zheng, J.; Gao, S.; Li, Y.; Zheng, Y.; Li, X.; Huang, J.; Niu, W.; Jiang, S.; Hao, C.; Yuan, Z.; Zhang, Y.; Wang, M.; Wang, Z. Z.; Peng, J.; Wang, A.; Wang, Y.; Sui, X.; Xu, W.; Hao, L.; Zheng, X.; Liu, S.; Guo, Q. 3D-Printed Cell-Free PCL-MECM Scaffold with Biomimetic Micro-Structure and Micro-Environment to Enhance in Situ Meniscus Regeneration. *Bioactive materials* **2021**, *6* (10), 3620–3633. <https://doi.org/10.1016/J.BIOACTMAT.2021.02.019>.
- (63) Jian, Z.; Zhuang, T.; Qinyu, T.; Liqing, P.; Kun, L.; Xujiang, L.; Diaodiao, W.; Zhen, Y.; Shuangpeng, J.; Xiang, S.; Jingxiang, H.; Shuyun, L.; Libo, H.; Peifu, T.; Qi, Y.; Quanyi, G. 3D Bioprinting of a Biomimetic Meniscal Scaffold for Application in Tissue Engineering. *Bioactive Materials* **2021**, *6* (6), 1711–1726. <https://doi.org/10.1016/j.bioactmat.2020.11.027>.

- 1  
2  
3 (64) Korpershoek, J. v.; de Ruijter, M.; Terhaard, B. F.; Hagmeijer, M. H.; Saris, D. B. F.;  
4 Castilho, M.; Malda, J.; Vonk, L. A. Potential of Melt Electrowritten Scaffolds Seeded  
5 with Meniscus Cells and Mesenchymal Stromal Cells. *International Journal of Molecular*  
6 *Sciences* **2021**, *22* (20). <https://doi.org/10.3390/ijms222011200>.  
7  
8  
9 (65) Melchels, F. P. W.; Blokzijl, M. M.; Levato, R.; Peiffer, Q. C.; Ruijter, M. de; Hennink,  
10 W. E.; Vermonden, T.; Malda, J. Hydrogel-Based Reinforcement of 3D Bioprinted  
11 Constructs. *Biofabrication* **2016**, *8* (3). <https://doi.org/10.1088/1758-5090/8/3/035004>.  
12  
13 (66) Costa, J. B.; Silva-Correia, J.; Oliveira, J. M.; Reis, R. L. Fast Setting Silk Fibroin Bioink  
14 for Bioprinting of Patient-Specific Memory-Shape Implants. *Advanced healthcare*  
15 *materials* **2017**, *6* (22). <https://doi.org/10.1002/ADHM.201701021>.  
16  
17 (67) Tognato, R.; Armiento, A. R.; Bonfrate, V.; Levato, R.; Malda, J.; Alini, M.; Eglin, D.;  
18 Giancane, G.; Serra, T. A Stimuli-Responsive Nanocomposite for 3D Anisotropic Cell-  
19 Guidance and Magnetic Soft Robotics. *Advanced Functional Materials* **2019**, *29*.  
20 <https://doi.org/10.1002/adfm.201804647>.  
21  
22 (68) Omidinia-Anarkoli, A.; Boesveld, S.; Tuvshindorj, U.; Rose, J. C.; Haraszti, T.; Laporte,  
23 L. de. An Injectable Hybrid Hydrogel with Oriented Short Fibers Induces Unidirectional  
24 Growth of Functional Nerve Cells. *Small* **2017**, *13* (36).  
25 <https://doi.org/10.1002/SMLL.201702207>.  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60